Breast cancer

Last updated

Breast cancer
Breast Cancer.png
An illustration of breast cancer
Specialty Oncology
Symptoms A lump in a breast, a change in breast shape, dimpling of the skin, fluid from the nipple, a newly inverted nipple, a red scaly patch of skin on the breast [1]
Risk factors Being female, obesity, lack of exercise, alcohol, hormone replacement therapy during menopause, ionizing radiation, early age at first menstruation, having children late in life or not at all, older age, prior breast cancer, family history of breast cancer, Klinefelter syndrome [1] [2] [3]
Diagnostic method Tissue biopsy [1]
TreatmentSurgery, radiation therapy, chemotherapy, hormonal therapy, targeted therapy [1]
Prognosis Five-year survival rate is approximately 85% (US, UK) [4] [5]
Frequency2.2 million affected (global, 2020) [6]
Deaths685,000 (global, 2020) [6]

Breast cancer is a cancer that develops from breast tissue. [7] Signs of breast cancer may include a lump in the breast, a change in breast shape, dimpling of the skin, milk rejection, fluid coming from the nipple, a newly inverted nipple, or a red or scaly patch of skin. [1] In those with distant spread of the disease, there may be bone pain, swollen lymph nodes, shortness of breath, or yellow skin. [8]


Risk factors for developing breast cancer include obesity, a lack of physical exercise, alcohol consumption, hormone replacement therapy during menopause, ionizing radiation, an early age at first menstruation, having children late in life (or not at all), older age, having a prior history of breast cancer, and a family history of breast cancer. [1] [2] [9] About five to ten percent of cases are the result of an inherited genetic predisposition, [1] including BRCA mutations among others. [1] Breast cancer most commonly develops in cells from the lining of milk ducts and the lobules that supply these ducts with milk. [1] Cancers developing from the ducts are known as ductal carcinomas, while those developing from lobules are known as lobular carcinomas. [1] There are more than 18 other sub-types of breast cancer. [2] Some, such as ductal carcinoma in situ, develop from pre-invasive lesions. [2] The diagnosis of breast cancer is confirmed by taking a biopsy of the concerning tissue. [1] Once the diagnosis is made, further tests are carried out to determine if the cancer has spread beyond the breast and which treatments are most likely to be effective. [1]

The balance of benefits versus harms of breast cancer screening is controversial. A 2013 Cochrane review found that it was unclear whether mammographic screening does more harm than good, in that a large proportion of women who test positive turn out not to have the disease. [10] A 2009 review for the US Preventive Services Task Force found evidence of benefit in those 40 to 70 years of age, [11] and the organization recommends screening every two years in women 50 to 74 years of age. [12] The medications tamoxifen or raloxifene may be used in an effort to prevent breast cancer in those who are at high risk of developing it. [2] Surgical removal of both breasts is another preventive measure in some high risk women. [2] In those who have been diagnosed with cancer, a number of treatments may be used, including surgery, radiation therapy, chemotherapy, hormonal therapy, and targeted therapy. [1] Types of surgery vary from breast-conserving surgery to mastectomy. [13] [14] Breast reconstruction may take place at the time of surgery or at a later date. [14] In those in whom the cancer has spread to other parts of the body, treatments are mostly aimed at improving quality of life and comfort. [14]

Outcomes for breast cancer vary depending on the cancer type, the extent of disease, and the person's age. [14] The five-year survival rates in England and the United States are between 80 and 90%. [15] [4] [5] In developing countries, five-year survival rates are lower. [2] Worldwide, breast cancer is the leading type of cancer in women, accounting for 25% of all cases. [16] In 2018, it resulted in two million new cases and 627,000 deaths. [17] It is more common in developed countries, [2] and is more than 100 times more common in cisgender women than in men, [15] [18] and 46 times more common in transgender women on gender-affirming hormone therapy than in cisgender men. [19]

Signs and symptoms

Common symptoms of breast cancer En Breast cancer illustrations.png
Common symptoms of breast cancer

Most people with breast cancer have no symptoms at the time of diagnosis; their tumor is detected by a breast cancer screening test. [20] For those who do have symptoms, a new lump in the breast is most common. Most breast lumps are not breast cancer, though lumps that are painless, hard, and with irregular edges are more likely to be cancerous. [21] Other symptoms include swelling or pain in the breast; dimpling, thickening, redness, or dryness of the breast skin; and pain, or inversion of the nipple. [21] Some may experience unusual discharge from the breasts, or swelling of the lymph nodes under the arms or along the collar bone. [21]

Some less common forms of breast cancer cause distinctive symptoms. Up to 5% of people with breast cancer have inflammatory breast cancer, where cancer cells block the lymph vessels of one breast, causing the breast to substantially swell and redden over three to six months. [22] Up to 3% of people with breast cancer have Paget's disease of the breast, with eczema-like red, scaly irritation on the nipple and areola. [23]

Advanced breast tumors can spread (metastasize) beyond the breast. The symptoms caused by metastatic breast cancer will depend on the location of metastasis. Common sites of metastasis include bone, liver, lung, and brain. [24] When cancer has reached such an invasive state, it is categorized as a stage 4 cancer, cancers of this state are often fatal. [25] Common symptoms of stage 4 cancer include unexplained weight loss, bone and joint pain, jaundice and neurological symptoms. These symptoms are called non-specific symptoms because they could be manifestations of many other illnesses. [26] Rarely breast cancer can spread to exceedingly uncommon sites such as peripancreatic lymph nodes causing biliary obstruction leading to diagnostic difficulties. [27]

Tumor in the breast visualized by Breast-Computertomography (Breast-CT) Brust Computertomographie mit Kontrastmittel Tumor.jpg
Tumor in the breast visualized by Breast-Computertomography (Breast-CT)

Most symptoms of breast disorders, including most lumps, do not turn out to represent underlying breast cancer. Less than 20% of lumps, for example, are cancerous, [28] and benign breast diseases such as mastitis and fibroadenoma of the breast are more common causes of breast disorder symptoms. [29]

Risk factors


Up to 80% of the variation in breast cancer frequency across countries is due to differences in reproductive history that impact a woman's levels of female sex hormones (estrogens). [30] Women who begin menstruating earlier (before age 12) or who have their first pregnancy later (after age 35) are at increased risk of developing breast cancer. [30] Those who lack functioning ovaries, breastfeed their children, or experience early menopause have reduced breast cancer risk. [30]

Hormone replacement therapy (HRT) to treat menopause is associated with only a small increased risk of breast cancer. [31] [32] [33] The level of risk also depends on the type of HRT, the duration of the treatment and the age of the person. Estrogen-only HRT, taken by people who had a hysterectomy, comes with an extremely low level of breast cancer risk. The most commonly taken combined HRT (estrogen and progestogen) is linked to a small risk of breast cancer. This risk is lower for women in their 50s and higher for older women. The risk increases with the duration of HRT. When HRT is taken for a year or less, there is no increased risk of breast cancer. HRT taken for more than five years comes with an increased risk but the risk reduces after the therapy is stopped. [32] [33]

In the 1980s, the abortion–breast cancer hypothesis posited that induced abortion increased the risk of developing breast cancer. [34] This hypothesis was the subject of extensive scientific inquiry, which concluded that neither miscarriages nor abortions are associated with a heightened risk for breast cancer. [35]

The use of hormonal birth control does not cause breast cancer for most women; [36] if it has an effect, it is small (on the order of 0.01% per user–year), temporary, and offset by the users' significantly reduced risk of ovarian and endometrial cancers. [37] Among those with a family history of breast cancer, use of modern oral contraceptives does not appear to affect the risk of breast cancer. [38]


All types of alcoholic beverages, including beer, wine, or liquor, cause breast cancer. NIH standard drink comparison.jpg
All types of alcoholic beverages, including beer, wine, or liquor, cause breast cancer.
Drinking alcohol, even at low levels, increases the risk of breast cancer
   Additional risk from drinking [39] [40]
   Original breast cancer risk (=100%)

Drinking alcoholic beverages increases the risk of breast cancer, even among very light drinkers (women drinking less than half of one alcoholic drink per day). [39] The risk is highest among heavy drinkers. [41] Globally, about one in ten cases of breast cancer is caused by women drinking alcoholic beverages. [41] Alcohol use is among the most common modifiable risk factors. [42]

Obesity and diabetes increase the risk of breast cancer. A high body mass index (BMI) causes 7% of breast cancers while diabetes is responsible for 2%. [43] [44] At the same time the correlation between obesity and breast cancer is not at all linear. Studies show that those who rapidly gain weight in adulthood are at higher risk than those who have been overweight since childhood. Likewise, excess fat in the midriff seems to induce a higher risk than excess weight carried in the lower body. [45] Dietary factors that may increase risk include a high-fat diet [46] and obesity-related high cholesterol levels. [47] [48]

Dietary iodine deficiency may also play a role in the development of breast cancer. [49]

Smoking tobacco appears to increase the risk of breast cancer, with the greater the amount smoked and the earlier in life that smoking began, the higher the risk. [50] In those who are long-term smokers, the relative risk is increased by 35% to 50%. [50]

A lack of physical activity has been linked to about 10% of cases. [51] Sitting regularly for prolonged periods is associated with higher mortality from breast cancer. The risk is not negated by regular exercise, though it is lowered. [52]

Actions to prevent breast cancer include not drinking alcoholic beverages, maintaining a healthy body composition, avoiding smoking and eating healthy food. Combining all of these (leading the healthiest possible lifestyle) would make almost a quarter of breast cancer cases worldwide preventable. [53] The remaining three-quarters of breast cancer cases cannot be prevented through lifestyle changes. [53]

Other risk factors include radiation [54] and circadian disruptions related to shift-work [55] and routine late-night eating. [56] A number of chemicals have also been linked, including polychlorinated biphenyls, polycyclic aromatic hydrocarbons, and organic solvents. [57] Although the radiation from mammography is a low dose, it is estimated that yearly screening from 40 to 80 years of age will cause approximately 225 cases of fatal breast cancer per million women screened. [58]


Around 10% of those with breast cancer have a family history of the disease or genetic factors that put them at higher risk. [59] Women who have had a first-degree relative (mother or sister) diagnosed with breast cancer are at a 30–50% increased risk of being diagnosed with breast cancer themselves. [60] In those with zero, one or two affected relatives, the risk of breast cancer before the age of 80 is 7.8%, 13.3%, and 21.1% with a subsequent mortality from the disease of 2.3%, 4.2%, and 7.6% respectively. [61]

Women with certain genetic variants are at higher risk of developing breast cancer. The most well known are variants of the BRCA genes BRCA1 and BRCA2. [60] Women with pathogenic variants in either gene have around a 70% chance of developing breast cancer in their lifetime, as well as an approximately 33% chance of developing ovarian cancer. [59] [60] Pathogenic variants in PALB2 – a gene whose product directly interacts with that of BRCA2 – also increase breast cancer risk; a woman with such a variant has around a 50% increased risk of developing breast cancer. [59] Variants in other tumor suppressor genes can also increase one's risk of developing breast cancer, namely p53 (causes Li–Fraumeni syndrome), PTEN (causes Cowden syndrome), and PALB1 . [60]

Other genetic predispositions include the density of the breast tissue and hormonal levels. Women with dense breast tissue are more likely to get tumors and are less likely to be diagnosed with breast cancer – because the dense tissue makes tumors less visible on mammograms. Furthermore, women with naturally high estrogen and progesterone levels are also at higher risk for tumor development. [62] [63]

Medical conditions

Breast changes like atypical ductal hyperplasia [64] and lobular carcinoma in situ, [65] [66] found in benign breast conditions such as fibrocystic breast changes, are correlated with an increased breast cancer risk.

Diabetes mellitus might also increase the risk of breast cancer. [67] Autoimmune diseases such as lupus erythematosus seem also to increase the risk for the acquisition of breast cancer. [68]


Ducts and lobules are the main locations of breast cancers. Lobules and ducts of the breast.jpg
Ducts and lobules are the main locations of breast cancers.
Overview of signal transduction pathways involved in programmed cell death. Mutations leading to loss of this ability can lead to cancer formation. Signal transduction pathways.svg
Overview of signal transduction pathways involved in programmed cell death. Mutations leading to loss of this ability can lead to cancer formation.

The major causes of sporadic breast cancer are associated with hormone levels. Breast cancer is promoted by estrogen. This hormone activates the development of breast throughout puberty, menstrual cycles and pregnancy. The imbalance between estrogen and progesterone during the menstrual phases causes cell proliferation. Moreover, oxidative metabolites of estrogen can increase DNA damage and mutations. Repeated cycling and the impairment of repair process can transform a normal cell into pre-malignant and eventually malignant cell through mutation. During the premalignant stage, high proliferation of stromal cells can be activated by estrogen to support the development of breast cancer. During the ligand binding activation, the ER can regulate gene expression by interacting with estrogen response elements within the promotor of specific genes. The expression and activation of ER due to lack of estrogen can be stimulated by extracellular signals. [69] Interestingly, the ER directly binding with the several proteins, including growth factor receptors, can promote the expression of genes related to cell growth and survival. [70]

Breast cancer, like other cancers, occurs because of an interaction between an environmental (external) factor and a genetically susceptible host. Normal cells divide as many times as needed, and stop. They attach to other cells and stay in place in tissues. Cells become cancerous when they lose their ability to stop dividing, to attach to other cells, to stay where they belong, and to die at the proper time.

Normal cells will self-destruct (programmed cell death) when they are no longer needed. Until then, cells are protected from programmed death by several protein clusters and pathways. One of the protective pathways is the PI3K/AKT pathway; another is the RAS/MEK/ERK pathway. Sometimes the genes along these protective pathways are mutated in a way that turns them permanently "on", rendering the cell incapable of self-destructing when it is no longer needed. This is one of the steps that causes cancer in combination with other mutations. Normally, the PTEN protein turns off the PI3K/AKT pathway when the cell is ready for programmed cell death. In some breast cancers, the gene for the PTEN protein is mutated, so the PI3K/AKT pathway is stuck in the "on" position, and the cancer cell does not self-destruct. [71]

Mutations that can lead to breast cancer have been experimentally linked to estrogen exposure. [72] Additionally, G-protein coupled estrogen receptors have been associated with various cancers of the female reproductive system including breast cancer. [73]

Abnormal growth factor signaling in the interaction between stromal cells and epithelial cells can facilitate malignant cell growth. [74] [75] In breast adipose tissue, overexpression of leptin leads to increased cell proliferation and cancer. [76]

Some mutations associated with cancer, such as p53, BRCA1 and BRCA2 , occur in mechanisms to correct errors in DNA. The inherited mutation in BRCA1 or BRCA2 genes can interfere with repair of DNA crosslinks and double-strand breaks (known functions of the encoded protein). [77] These carcinogens cause DNA damage such as DNA crosslinks and double-strand breaks that often require repairs by pathways containing BRCA1 and BRCA2. [78] [79]

GATA-3 directly controls the expression of estrogen receptor (ER) and other genes associated with epithelial differentiation, and the loss of GATA-3 leads to loss of differentiation and poor prognosis due to cancer cell invasion and metastasis. [80]


Cartoon of a mammogram, with the breast to be imaged pressed between two plates. MammographyinprocessGraphic.jpg
Cartoon of a mammogram, with the breast to be imaged pressed between two plates.

Breast cancer screening refers to testing otherwise-healthy women for breast cancer in an attempt to diagnose breast tumors early when treatments are more successful. The most common screening test for breast cancer is low-dose X-ray imaging of the breast, called mammography. [81] Each breast is pressed between two plates and imaged. Tumors can appear unusually dense within the breast, distort the shape of surrounding tissue, or cause small dense flecks called microcalcifications. [82] Radiologists generally report mammogram results on a standardized scale – the six-point Breast Imaging-Reporting and Data System (BI-RADS) is the most common globally – where a higher number corresponds to a greater risk of a cancerous tumor. [83] [84]

A mammogram also reveals breast density; dense breast tissue appears opaque on a mammogram and can obscure tumors. [85] [86] BI-RADS categorizes breast density into four categories. Mammography can detect around 90% of breast tumors in the least dense breasts (called "fatty" breasts), but just 60% in the most dense breasts (called "extremely dense"). [87] Women with particularly dense breasts can instead be screened by ultrasound, magnetic resonance imaging (MRI), or tomosynthesis, all of which more sensitively detect breast tumors. [88]

Regular screening mammography reduces breast cancer deaths by at least 20%. [89] Most medical guidelines recommend annual screening mammograms for women aged 50–70. [90] Screening also reduces breast cancer mortality in women aged 40–49, and some guidelines recommend annual screening in this age group as well. [90] [91] For women at high risk for developing breast cancer, most guidelines recommend adding MRI screening to mammography, to increase the chance of detecting potentially dangerous tumors. [88] Regularly feeling one's own breasts for lumps or other abnormalities, called breast self-examination, does not reduce a person's chance of dying from breast cancer. [92] Clinical breast exams, where a health professional feels the breasts for abnormalities, are common; [93] whether they reduce the risk of dying from breast cancer is not known. [81]

Mammograms showing a normal breast (left) and a breast with cancer (right) Mammo breast cancer wArrows.jpg
Mammograms showing a normal breast (left) and a breast with cancer (right)

For the average woman, the US Preventive Services Task Force and American College of Physicians recommends mammography every two years in women between the ages of 50 and 74, [12] [94] the Council of Europe recommends mammography between 50 and 69 with most programs using a 2-year frequency, [95] while the European Commission recommends mammography between the ages of 45 and 75 every two to three years, [96] and in Canada screening is recommended between the ages of 50 and 74 at a frequency of two to three years. [97] The American Cancer Society also endorses that women ages 40 and older receive mammograms annually. [98] These task force reports point out that in addition to unnecessary surgery and anxiety, the risks of more frequent mammograms include a small but significant increase in breast cancer induced by radiation. [99]


Needle breast biopsy Needle Breast Biopsy.png
Needle breast biopsy

Those who have a suspected tumor from a mammogram or physical exam first undergo additional imaging – typically a second "diagnostic" mammogram and ultrasound – to confirm its presence and location. [20] A biopsy is then taken of the suspected tumor. Breast biopsy is typically done by core needle biopsy, with a hollow needle used to collect tissue from the area of interest. [100] Suspected tumors that appear to be filled with fluid are often instead sampled by fine-needle aspiration. [100] [101] Around 10–20% of breast biopsies are positive for cancer. [102] Most biopsied breast masses are instead caused by fibrocystic breast changes, a term that encompasses the benign growth of small pockets of fluid, cell growth, or fibrous tissue. [102]


Breast cancers are classified by several grading systems, each of which assess a tumor characteristic that impacts a person's prognosis. First, a tumor is classified by the tissue it arises from, or the appearance of the tumor tissue under a microscope. Most breast cancers (85%) are ductal carcinoma – derived from the lining of the mammary ducts. 10% are lobular carcinoma – derived from the mammary lobes – or mixed ductal/lobular carcinoma. [104] Rarer types include mucinous carcinoma (around 2.5% of cases; surrounded by mucin), tubular carcinoma (1.5%; full of small tubes of epithelial cells), medullary carcinoma (1%; resembling "medullary" or middle-layer tissue), and papillary carcinoma (1%; covered in finger-like growths). [104] Oftentimes a biopsy reveals cells that are cancerous but have not yet spread beyond their original location. This condition, called carcinoma in situ, is often considered "precancerous" rather than a dangerous cancer itself. [105] Those with ductal carcinoma in situ (in the mammary ducts) are at increased risk for developing true invasive breast cancer – around a third develop breast cancer within five years. [105] Lobular carcinoma in situ (in the mammary lobes) rarely causes a noticeable lump, and is often found incidentally during a biopsy for another reason. It is commonly spread throughout both breasts. Those with lobular carcinoma in situ also have an increased risk of developing breast cancer – around 1% develop breast cancer each year. However, their risk of dying of breast cancer is no higher than the rest of the population. [105]

Invasive tumor tissue is assigned a grade based on how distinct it appears from healthy breast. [106] Breast tumors are graded based on three features: the proportion of cancer cells that form tubules, the appearance of the cell nucleus, and how many cells are actively replicating. [107] Each feature is scored on a three-point scale, with a higher score indicating less healthy looking tissue. A grade is assigned based on the sum of the three scores. Combined scores of 3, 4, or 5 represent grade 1, a slower-growing cancer. Scores of 6 or 7 represent grade 2. Scores of 8 or 9 represent grade 3, a faster-growing, more aggressive cancer. [106]

In addition to grading, tumor biopsy samples are tested by immunohistochemistry to determine if the tissue contains the proteins estrogen receptor (ER), progesterone receptor (PR), or human epidermal growth factor receptor 2 (HER2). [108] Tumors containing either ER or PR are called "hormone receptor-positive" and can be treated with hormone therapies. [109] Around 15 to 20% of tumors contain HER2; these can be treated with HER2-targeted therapies. [110] The remainder that do not contain ER, PR, or HER2 are called "triple-negative" tumors, and tend to grow more quickly than other breast cancer types. [109]

After the tumor is evaluated, the breast cancer case is staged using the American Joint Committee on Cancer and Union for International Cancer Control's TNM staging system. [111] Scores are assigned based on characteristics of the tumor (T), lymph nodes (N), and any metastases (M). [112] T scores are determine by the size and extent of the tumor. Tumors less than 20  millimeters (mm) across are designated T1. Tumors 20–50 mm across are T2. A tumor greater than 50 mm across is T3. Tumors that extend to the chest wall or to the skin are designated T4. [113] N scores are based on whether the cancer has spread to nearby lymph nodes. N0 indicates no spread to the lymph nodes. N1 is for tumors that have spread to the closest axillary lymph nodes (called "level I" and "level II" axillary lymph nodes, in the armpit). N2 is for spread to the intramammary lymph nodes (on the other side of the breast, near the chest center), or for axillary lymph nodes that appear attached to each other or to the tissue around them (a sign of more severely affected tissue). [114] N3 designates tumors that have spread to the highest axillary lymph nodes (called "level 3" axillary lymph nodes, above the armpit near the shoulder), to the supraclavicular lymph nodes (along the neck), or to both the axillary and intramammary lymph nodes. [114] The M score is binary: M0 indicates no evidence metastases; M1 indicates metastases have been detected. [115]

TNM scores are then combined with tumor grades and ER/PR/HER2 status to calculate a cancer case's "prognostic stage group". Stage groups range from I (best prognosis) to IV (worst prognosis), with groups I, II, and III further divided into subgroups IA, IB, IIA, IIB, IIIA, IIIB, and IIIC. In general, tumors of higher T and N scores and higher grades are assigned higher stage groups. Tumors that are ER, PR, and HER2 positive are slightly lower stage group than those that are negative. Tumors that have metastasized are stage IV, regardless of the scored other characteristics. [116]



Women can reduce their risk of breast cancer by maintaining a healthy weight, reducing alcohol use, increasing physical activity, and breastfeeding. [117] These modifications might prevent 38% of breast cancers in the US, 42% in the UK, 28% in Brazil, and 20% in China. [117] The benefits with moderate exercise such as brisk walking are seen at all age groups including postmenopausal women. [117] [118] High levels of physical activity reduce the risk of breast cancer by about 14%. [119] Strategies that encourage regular physical activity and reduce obesity could also have other benefits, such as reduced risks of cardiovascular disease and diabetes. [120] A study that included data from 130,957 women of European ancestry found "strong evidence that greater levels of physical activity and less sedentary time are likely to reduce breast cancer risk, with results generally consistent across breast cancer subtypes". [121]

The American Cancer Society and the American Society of Clinical Oncology advised in 2016 that people should eat a diet high in vegetables, fruits, whole grains, and legumes. [122] Eating foods rich in soluble fiber contributes to reducing breast cancer risk. [123] [124] High intake of citrus fruit has been associated with a 10% reduction in the risk of breast cancer. [125] Marine omega-3 polyunsaturated fatty acids appear to reduce the risk. [126] High consumption of soy-based foods may reduce risk. [127]

Preventive surgery

Removal of the breasts before breast cancer develops (called preventive mastectomy) reduces the risk of developing breast cancer by more than 95%. [128] In women genetically predisposed to developing breast cancer, preventive mastectomy reduces their risk of dying from breast cancer. [128] For those at normal risk, preventive mastectomy does not reduce their chance of dying, and so is generally not recommended. [128] Removing the second breast in a person who has breast cancer (contralateral risk‐reducing mastectomy or CRRM) may reduce the risk of cancer in the second breast, but it is not clear whether removing the second breast improves the chance of survival. [129] An increasing number of women who test positive for faulty BRCA1 or BRCA2 genes choose to have risk-reducing surgery. The average waiting time for undergoing the procedure is two years, which is much longer than recommended. [130] [131]


Selective estrogen receptor modulators (SERMs) reduce the risk of breast cancer but increase the risk of thromboembolism and endometrial cancer. [132] There is no overall change in the risk of death. [132] [133] They are thus not recommended for the prevention of breast cancer in women at average risk but it is recommended they be offered for those at high risk and over the age of 35. [134] The benefit of breast cancer reduction continues for at least five years after stopping a course of treatment with these medications. [135] Aromatase inhibitors (such as exemestane and anastrozole) may be more effective than SERMs (such as tamoxifen) at reducing breast cancer risk and they are not associated with an increased risk of endometrial cancer and thromboembolism. [136]


The management of breast cancer depends on the affected person's health, the cancer case's molecular characteristics, and how far the tumor has spread at the time of diagnosis.

Local tumors

Chest after right breast mastectomy Mastectomie 02.jpg
Chest after right breast mastectomy

Those whose tumors have not spread beyond the breast often undergo surgery to remove the tumor and some surrounding breast tissue. [137] The surgery method is typically chosen to spare as much healthy breast tissue as possible, removing just the tumor (lumpectomy) or a larger part of the breast (partial mastectomy). Those with large or multiple tumors, high genetic risk of subsequent cancers, or who are unable to receive radiation therapy may instead opt for full removal of the affected breast(s) (full mastectomy). [137]

After surgery, most receive radiotherapy to decrease the chance of the cancer returning. Those who had a mastectomy receive radiation to the chest wall and mastectomy scar; those who had breast-sparing surgery receive radiation to the whole breast. [138] If cancerous cells have spread to nearby lymph nodes, those lymph nodes will be irradiated as well. [138] Radiation is typically given five days per week, for up to seven weeks. [138] Radiotherapy for breast cancer is typically delivered via external beam radiotherapy, where a device focuses radiation beams onto the targeted parts of the body. Instead, some undergo brachytherapy, where radioactive material is placed into a device inserted at the surgical site the tumor was removed from. Fresh radioactive material is added twice a day for five days, then the device is removed. [138] Surgery plus radiation typically eliminates a person's breast tumor. Less than 5% of those treated have their tumor recur. [137]


Medications used after and in addition to surgery are called adjuvant therapy. Chemotherapy or other types of therapy prior to surgery are called neoadjuvant therapy. Aspirin may reduce mortality from breast cancer when used with other treatments. [139] [140]

There are currently three main groups of medications used for adjuvant breast cancer treatment: hormone-blocking agents, chemotherapy, and monoclonal antibodies.

Hormonal therapy

Some breast cancers require estrogen to continue growing. They can be identified by the presence of estrogen receptors (ER+) and progesterone receptors (PR+) on their surface (sometimes referred to together as hormone receptors). These ER+ cancers can be treated with drugs that either block the receptors, e.g. tamoxifen, or alternatively block the production of estrogen with an aromatase inhibitor, e.g. anastrozole [141] or letrozole. The use of tamoxifen is recommended for 10 years. [142] Tamoxifen increases the risk of postmenopausal bleeding, endometrial polyps, hyperplasia, and endometrial cancer; using tamoxifen with an intrauterine system releasing levonorgestrel might increase vaginal bleeding after one to two years, but reduces somewhat endometrial polyps and hyperplasia, but not necessarily endometrial cancer. [143] Letrozole is recommended for five years.

Aromatase inhibitors are only suitable for women after menopause; however, in this group, they appear better than tamoxifen. [144] This is because the active aromatase in postmenopausal women is different from the prevalent form in premenopausal women, and therefore these agents are ineffective in inhibiting the predominant aromatase of premenopausal women. [145] Aromatase inhibitors should not be given to premenopausal women with intact ovarian function (unless they are also on treatment to stop their ovaries from working). [146] CDK inhibitors can be used in combination with endocrine or aromatase therapy. [147]


Chemotherapy is predominantly used for cases of breast cancer in stages 2–4, and is particularly beneficial in estrogen receptor-negative (ER-) disease. The chemotherapy medications are administered in combinations, usually for periods of 3–6 months. One of the most common regimens, known as "AC", combines cyclophosphamide with doxorubicin. Sometimes a taxane drug, such as docetaxel, is added, and the regime is then known as "CAT". Another common treatment is cyclophosphamide, methotrexate, and fluorouracil (or "CMF"). Most chemotherapy medications work by destroying fast-growing and/or fast-replicating cancer cells, either by causing DNA damage upon replication or by other mechanisms. However, the medications also damage fast-growing normal cells, which may cause serious side effects. Damage to the heart muscle is the most dangerous complication of doxorubicin, for example.[ citation needed ]

Monoclonal antibodies

Trastuzumab, a monoclonal antibody to HER2, has improved the five-year disease free survival of stage 1–3 HER2-positive breast cancers to about 87% (overall survival 95%). [148] Between 25% and 30% of breast cancers overexpress the HER2 gene or its protein product, [149] and overexpression of HER2 in breast cancer is associated with increased disease recurrence and worse prognosis. Trastuzumab, however, is very expensive, and its use may cause serious side effects (approximately 2% of people who receive it develop significant heart damage). [150] Another antibody pertuzumab prevents HER2 dimerization and is recommended together with trastuzumab and chemotherapy in severe disease. [151] [152]

Targeted therapy

Elacestrant (Orserdu) was approved for medical use in the United States in January 2023. [153] [154]

Capivasertib (Truqap) was approved for medical use in the United States in November 2023. [155] [156] [157]

Follow-up care

Breasts after double mastectomy followed by nipple-sparing reconstruction with implants Breast reconstruction 15.jpg
Breasts after double mastectomy followed by nipple-sparing reconstruction with implants

Care after primary breast cancer treatment, otherwise called 'follow-up care', can be intensive involving regular laboratory tests in asymptomatic people to try to achieve earlier detection of possible metastases. A review has found that follow-up programs involving regular physical examinations and yearly mammography alone are as effective as more intensive programs consisting of laboratory tests in terms of early detection of recurrence, overall survival and quality of life. [158]

Multidisciplinary rehabilitation programmes, often including exercise, education and psychological help, may produce short-term improvements in functional ability, psychosocial adjustment and social participation in people with breast cancer. [159]

Upper limb problems such as shoulder and arm pain, weakness and restricted movement are a common side effect after radiotherapy or breast cancer surgery. [160] According to research in the UK, an exercise programme started 7–10 days after surgery can reduce upper limb problems. [161] [162]

Psychological Aspects and Supportive care

Chemotherapy related cognitive impairment (CRCI) is a psychological aspect commonly associated with breast cancer patients, with about 10-40% of patients reporting symptoms. [163] [164] [165] Beginning in the late 1980's, evidence began to emerge that indicated problems with cognitive abilities such as executive functioning, verbal fluency, attention, and speed of processing for breast cancer patients after receiving chemotherapy. [166] [165] Research points to the neurotoxicity of chemotherapy in causing these cognitive impairments, yet there has been occurrence of breast cancer patients reporting cognitive impairments before chemotherapy has even begun. [166] [164] [167] Factors such as age, menopausal status, depression, anxiety, fatigue, and distress may additionally contribute this "brain fog". [166] [164] Patients experiencing cognitive impairment may have difficulty with their careers, duties and usual routines, which may cause frustration and thus affect quality of life. [164] [168] While impairments may last for some patients up to 10 years [163] [169] , fortunately most symptoms subside within four years after treatment. [165] Management wise, there are several proposed pharmaceutical options such as methylphenidate, erythropoietin and modafinil. [163] [170] [171]

In women with non-metastatic breast cancer, psychological interventions such as cognitive behavioral therapy can have positive effects on outcomes such as cognitive impairment, anxiety, depression and mood disturbance, and can also improve the quality of life. [172] [173] [174] Physical activity interventions, yoga and meditation may also have beneficial effects on health related quality of life, cognitive impairment, anxiety, fitness and physical activity in women with breast cancer following adjuvant therapy. [175] [173] [174] [176]

Breast cancer survivors have an increased risk for cardiovascular death, heart failure, and atrial fibrilation, when compared to the general population. [177]


Breast cancer survival by stage [178]
Stage Five-year survival

The stage of the breast cancer is the most important component of traditional classification methods of breast cancer, because it has a greater effect on the prognosis than the other considerations. Staging takes into consideration size, local involvement, lymph node status and whether metastatic disease is present. The higher the stage at diagnosis, the poorer the prognosis. The stage is raised by the invasiveness of disease to lymph nodes, chest wall, skin or beyond, and the aggressiveness of the cancer cells. The stage is lowered by the presence of cancer-free zones and close-to-normal cell behavior (grading). Size is not a factor in staging unless the cancer is invasive. For example, ductal carcinoma in situ (DCIS) involving the entire breast will still be stage zero and consequently an excellent prognosis.

Younger women with an age of less than 40 years or women over 80 years tend to have a poorer prognosis than post-menopausal women due to several factors. Their breasts may change with their menstrual cycles, they may be nursing infants, and they may be unaware of changes in their breasts. Therefore, younger women are usually at a more advanced stage when diagnosed. There may also be biological factors contributing to a higher risk of disease recurrence for younger women with breast cancer. [180]


Age-standardized death from breast cancer per 100,000 inhabitants in 2004
.mw-parser-output .col-begin{border-collapse:collapse;padding:0;color:inherit;width:100%;border:0;margin:0}.mw-parser-output .col-begin-small{font-size:90%}.mw-parser-output .col-break{vertical-align:top;text-align:left}.mw-parser-output .col-break-2{width:50%}.mw-parser-output .col-break-3{width:33.3%}.mw-parser-output .col-break-4{width:25%}.mw-parser-output .col-break-5{width:20%}@media(max-width:720px){.mw-parser-output .col-begin,.mw-parser-output .col-begin>tbody,.mw-parser-output .col-begin>tbody>tr,.mw-parser-output .col-begin>tbody>tr>td{display:block!important;width:100%!important}.mw-parser-output .col-break{padding-left:0!important}}
no data
>22 Breast cancer world map - Death - WHO2004.svg
Age-standardized death from breast cancer per 100,000 inhabitants in 2004

Breast cancer is the most common invasive cancer in women in most countries, accounting for 30% of cancer cases in women. [182] [59] In 2022, an estimated 2.3 million women were diagnosed with breast cancer, and 670,000 died of the disease. [182] The incidence of breast cancer is rising by around 3% per year, as populations in many countries are getting older. [183]

Rates of breast cancer vary across the world, but generally correlate with wealth. [183] Around 1 in 12 women are diagnosed with breast cancer in wealthier countries, compared to 1 in 27 in lower income countries. [182] Most of that difference is due to differences in menstrual and reproductive histories – women in wealthier countries tend to begin menstruating earlier and have children later, both factors that increase risk of developing breast cancer. [184] People in lower income countries tend to have less access to breast cancer screening and treatments, and so breast cancer death rates tend to be higher. [183] 1 in 71 women die of breast cancer in wealthy countries, while 1 in 48 die of the disease in lower income countries. [182]

Breast cancer predominantly occurs in women, and risk increases with age. [185] Most breast cancers develop in women over 50. Women in their early 50s are twice as more likely to develop breast cancer than women in their early 40s. [43] Breast cancer is strongly related to age with only 5% of all breast cancers occurring in women under 40 years old. [186]


Breast cancer surgery in 18th century Louis-Jacques Goussier Enzyklopadie Diderot Pl XXIX.jpg
Breast cancer surgery in 18th century

Because of its visibility, breast cancer was the form of cancer most often described in ancient documents. [187] :9–13 Because autopsies were rare, cancers of the internal organs were essentially invisible to ancient medicine. Breast cancer, however, could be felt through the skin, and in its advanced state often developed into fungating lesions: the tumor would become necrotic (die from the inside, causing the tumor to appear to break up) and ulcerate through the skin, weeping fetid, dark fluid. [187] :9–13

The oldest discovered evidence of breast cancer is from Egypt and dates back 4200 years, to the Sixth Dynasty. [188] The study of a woman's remains from the necropolis of Qubbet el-Hawa showed the typical destructive damage due to metastatic spread. [188] The Edwin Smith Papyrus describes eight cases of tumors or ulcers of the breast that were treated by cauterization. The writing says about the disease, "There is no treatment." [189] For centuries, physicians described similar cases in their practices, with the same conclusion. Ancient medicine, from the time of the Greeks through the 17th century, was based on humoralism, and thus believed that breast cancer was generally caused by imbalances in the fundamental fluids that controlled the body, especially an excess of black bile. [187] :32 Alternatively it was seen as divine punishment. [190]

Mastectomy for breast cancer was performed at least as early as AD 548, when it was proposed by the court physician Aetios of Amida to Theodora. [187] :9–13 It was not until doctors achieved greater understanding of the circulatory system in the 17th century that they could link breast cancer's spread to the lymph nodes in the armpit. In the early 18th century the French surgeon Jean Louis Petit performed total mastectomies that included removing the axillary lymph nodes, as he recognized that this reduced recurrence. [191] Petit's work built on the methods of the surgeon Bernard Peyrilhe, who in the 17th century additionally removed the pectoral muscle underlying the breast, as he judged that this greatly improved the prognosis. [192] But poor results and the considerable risk to the patient meant that physicians did not share the opinion of surgeons such as Nicolaes Tulp, who in the 17th century proclaimed "the sole remedy is a timely operation." The eminent surgeon Richard Wiseman documented in the mid-17th century that following 12 mastectomies, two patients died during the operation, eight patients died shortly after the operation from progressive cancer and only two of the 12 patients were cured. [193] :6 Physicians were conservative in the treatment they prescribed in the early stages of breast cancer. Patients were treated with a mixture of detox purges, blood letting and traditional remedies that were supposed to lower acidity, such as the alkaline arsenic. [194] :24

When in 1664 Anne of Austria was diagnosed with breast cancer, the initial treatment involved compresses saturated with hemlock juice. When the lumps increased the King's physician commenced a treatment with arsenic ointments. [194] :25 The royal patient died 1666 in atrocious pain. [194] :26 Each failing treatment for breast cancer led to the search for new treatments, spurring a market in remedies that were advertised and sold by quacks, herbalists, chemists and apothecaries. [195] The lack of anesthesia and antiseptics made mastectomy a painful and dangerous ordeal. [193] In the 18th century, a wide variety of anatomical discoveries were accompanied by new theories about the cause and growth of breast cancer. The investigative surgeon John Hunter claimed that neural fluid generated breast cancer. Other surgeons proposed that milk within the mammary ducts led to cancerous growths. Theories about trauma to the breast as cause for malignant changes in breast tissue were advanced. The discovery of breast lumps and swellings fueled controversies about hard tumors and whether lumps were benign stages of cancer. Medical opinion about necessary immediate treatment varied. [193] :5 The surgeon Benjamin Bell advocated removal of the entire breast, even when only a portion was affected. [196]

Radical mastectomy, Halsted's surgical papers William Stewart Halsted, Surgical papers Wellcome L0004968.jpg
Radical mastectomy, Halsted's surgical papers

Breast cancer was uncommon until the 19th century, when improvements in sanitation and control of deadly infectious diseases resulted in dramatic increases in lifespan. Previously, most women had died too young to have developed breast cancer. [197] In 1878, an article in Scientific American described historical treatment by pressure intended to induce local ischemia in cases when surgical removal were not possible. [198] William Stewart Halsted started performing radical mastectomies in 1882, helped greatly by advances in general surgical technology, such as aseptic technique and anesthesia. The Halsted radical mastectomy often involved removing both breasts, associated lymph nodes, and the underlying chest muscles. This often led to long-term pain and disability, but was seen as necessary to prevent the cancer from recurring. [187] :102–106 Before the advent of the Halsted radical mastectomy, 20-year survival rates were only 10%; Halsted's surgery raised that rate to 50%. [187] :1

Breast cancer staging systems were developed in the 1920s and 1930s to determining the extent to which a cancer has developed by growing and spreading. [187] :102–106 The first case-controlled study on breast cancer epidemiology was done by Janet Lane-Claypon, who published a comparative study in 1926 of 500 breast cancer cases and 500 controls of the same background and lifestyle for the British Ministry of Health. [199] Radical mastectomies remained the standard of care in the USA until the 1970s, but in Europe, breast-sparing procedures, often followed by radiation therapy, were generally adopted in the 1950s. [187] :102–106 In 1955 George Crile Jr. published Cancer and Common Sense arguing that cancer patients needed to understand available treatment options. Crile became a close friend of the environmentalist Rachel Carson, who had undergone a Halsted radical mastectomy in 1960 to treat her malign breast cancer. [200] :39–40 The US oncologist Jerome Urban promoted super radical mastectomies, taking even more tissue, until 1963, when the ten-year survival rates proved equal to the less-damaging radical mastectomy. [187] :102–106 Carson died in 1964 and Crile went on to published a wide variety of articles, both in the popular press and in medical journals, challenging the widespread use of the Halsted radical mastectomy. In 1973 Crile published What Women Should Know About the Breast Cancer Controversy. When in 1974 Betty Ford was diagnosed with breast cancer, the options for treating breast cancer were openly discussed in the press. [200] :58 During the 1970s, a new understanding of metastasis led to perceiving cancer as a systemic illness as well as a localized one, and more sparing procedures were developed that proved equally effective. [201]

In the 1980s and 1990s, thousands of women who had successfully completed standard treatment then demanded and received high-dose bone marrow transplants, thinking this would lead to better long-term survival. However, it proved completely ineffective, and 15–20% of women died because of the brutal treatment. [202] :200–203 The 1995 reports from the Nurses' Health Study and the 2002 conclusions of the Women's Health Initiative trial conclusively proved that HRT significantly increased the incidence of breast cancer. [202]

Society and culture

Before the 20th century, breast cancer was feared and discussed in hushed tones, as if it were shameful. As little could be safely done with primitive surgical techniques, women tended to suffer silently rather than seeking care.[ citation needed ] When surgery advanced, and long-term survival rates improved, women began raising awareness of the disease and the possibility of successful treatment. The "Women's Field Army", run by the American Society for the Control of Cancer (later the American Cancer Society) during the 1930s and 1940s was one of the first organized campaigns. In 1952, the first peer-to-peer support group, called "Reach to Recovery", began providing post-mastectomy, in-hospital visits from women who had survived breast cancer. [202] :37–38

The breast cancer movement of the 1980s and 1990s developed out of the larger feminist movements and women's health movement of the 20th century. [202] :4 This series of political and educational campaigns, partly inspired by the politically and socially effective AIDS awareness campaigns, resulted in the widespread acceptance of second opinions before surgery, less invasive surgical procedures, support groups, and other advances in care. [203]

Pink ribbon

The pink ribbon is a symbol to show support for breast cancer awareness. Pink ribbon.svg
The pink ribbon is a symbol to show support for breast cancer awareness.

A pink ribbon is the most prominent symbol of breast cancer awareness. Pink ribbons, which can be made inexpensively, are sometimes sold as fundraisers, much like poppies on Remembrance Day. They may be worn to honor those who have been diagnosed with breast cancer, or to identify products that the manufacturer would like to sell to consumers that are interested in breast cancer. [202] :27–72 In the 1990s, breast cancer awareness campaigns were launched by US-based corporations. As part of these cause-related marketing campaigns, corporations donated to a variety of breast cancer initiatives for every pink ribbon product that was purchased. [204] :132–133 The Wall Street Journal noted that "the strong emotions provoked by breast cancer translate to a company's bottom line". While many US corporations donated to existing breast cancer initiatives, others such as Avon established their own breast cancer foundations on the back of pink ribbon products. [204] :135–136

Wearing or displaying a pink ribbon has been criticized by the opponents of this practice as a kind of slacktivism, because it has no practical positive effect. It has also been criticized as hypocrisy, because some people wear the pink ribbon to show good will towards women with breast cancer, but then oppose these women's practical goals, like patient rights and anti-pollution legislation. [202] :366–368 [205] Critics say that the feel-good nature of pink ribbons and pink consumption distracts society from the lack of progress on preventing and curing breast cancer. [202] :365–366 It is also criticized for reinforcing gender stereotypes and objectifying women and their breasts. [202] :372–374 Breast Cancer Action launched the "Think Before You Pink" campaign in 2002 against pinkwashing, to target businesses that have co-opted the pink campaign to promote products that cause breast cancer, such as alcoholic beverages. [206]

Breast cancer culture

In her 2006 book Pink Ribbons, Inc.: Breast Cancer and the Politics of Philanthropy Samantha King claimed that breast cancer has been transformed from a serious disease and individual tragedy to a market-driven industry of survivorship and corporate sales pitch. [207] In 2010 Gayle Sulik argued that the primary purposes or goals of breast cancer culture are to maintain breast cancer's dominance as the pre-eminent women's health issue, to promote the appearance that society is doing something effective about breast cancer, and to sustain and expand the social, political, and financial power of breast cancer activists. [202] :57 In the same year Barbara Ehrenreich published an opinion piece in Harper's Magazine , lamenting that in breast cancer culture, breast cancer therapy is viewed as a rite of passage rather than a disease. To fit into this mold, the woman with breast cancer needs to normalize and feminize her appearance, and minimize the disruption that her health issues cause anyone else. Anger, sadness, and negativity must be silenced. As with most cultural models, people who conform to the model are given social status, in this case as cancer survivors. Women who reject the model are shunned, punished and shamed. The culture is criticized for treating adult women like little girls, as evidenced by "baby" toys such as pink teddy bears given to adult women. [208]


In 2009 the US science journalist Christie Aschwanden criticized that the emphasis on breast cancer screening may be harming women by subjecting them to unnecessary radiation, biopsies, and surgery. One-third of diagnosed breast cancers might recede on their own. [209] Screening mammography efficiently finds non-life-threatening, asymptomatic breast cancers and precancers, even while overlooking serious cancers. According to the cancer researcher H. Gilbert Welch, screening mammography has taken the "brain-dead approach that says the best test is the one that finds the most cancers" rather than the one that finds dangerous cancers. [209]

In 2002 it was noted that as a result of breast cancer's high visibility, the statistical results can be misinterpreted, such as the claim that one in eight women will be diagnosed with breast cancer during their lives – a claim that depends on the unrealistic assumption that no woman will die of any other disease before the age of 95. [187] :199–200 By 2010 the breast cancer survival rate in Europe was 91% at one years and 65% at five years. In the USA the five-year survival rate for localized breast cancer was 96.8%, while in cases of metastases it was only 20.6%. Because the prognosis for breast cancer was at this stage relatively favorable, compared to the prognosis for other cancers, breast cancer as cause of death among women was 13.9% of all cancer deaths. The second most common cause of death from cancer in women was lung cancer, the most common cancer worldwide for men and women. The improved survival rate made breast cancer the most prevalent cancer in the world. In 2010 an estimated 3.6 million women worldwide have had a breast cancer diagnosis in the past five years, while only 1.4 million male or female survivors from lung cancer were alive. [210]

Health disparities in breast cancer

There are ethnic disparities in the mortality rates for breast cancer as well as in breast cancer treatment. Breast cancer is the most prevalent cancer affecting women of every ethnic group in the United States. Breast cancer incidence among black women aged 45 and older is higher than that of white women in the same age group. White women aged 60–84 have higher incidence rates of breast cancer than Black women. Despite this, Black women at every age are more likely to succumb to breast cancer. [211]

Breast cancer treatment has improved greatly over the years, but black women are still less likely to obtain treatment compared to white women. [211] Risk factors such as socioeconomic status, late-stage, or breast cancer at diagnosis, genetic differences in tumor subtypes, differences in health care access all contribute to these disparities. Socioeconomic determinants affecting the disparity in breast cancer illness include poverty, culture, as well as social injustice. In Hispanic women, the incidence of breast cancer is lower than in non-Hispanic women but is often diagnosed at a later stage than white women with larger tumors.

Black women are usually diagnosed with breast cancer at a younger age than white women. The median age of diagnosis for Black women is 59, in comparison to 62 in White women. The incidence of breast cancer in Black women has increased by 0.4% per year since 1975 and 1.5% per year among Asian/Pacific Islander women since 1992. Incidence rates were stable for non-Hispanic White, Hispanics, and Native women. The five-year survival rate is noted to be 81% in Black women and 92% in White women. Chinese and Japanese women have the highest survival rates. [211]

Poverty is a major driver for disparities related to breast cancer. Low-income women are less likely to undergo breast cancer screening and thus are more likely to have a late-stage diagnosis. [211] Ensuring women of all ethnic groups receive equitable health care including breast screening, can positively affect these disparities. [212]


Pregnancy at an early age decreases the risk of developing breast cancer later in life. [213] The risk of breast cancer also declines with the number of children a woman has. [213] Breast cancer then becomes more common in the five to ten years following pregnancy but then becomes less common than among the general population. [214] These cancers are known as postpartum breast cancer and have worse outcomes including an increased risk of distant spread of disease and mortality. [215] Other cancers found during or shortly after pregnancy appear at approximately the same rate as other cancers in women of a similar age. [216]

Diagnosing new cancer in a pregnant woman is difficult, in part because any symptoms are commonly assumed to be a normal discomfort associated with pregnancy. [216] As a result, cancer is typically discovered at a somewhat later stage than average in many pregnant or recently pregnant women. Some imaging procedures, such as MRIs (magnetic resonance imaging), CT scans, ultrasounds, and mammograms with fetal shielding are considered safe during pregnancy; some others, such as PET scans are not. [216]

Treatment is generally the same as for non-pregnant women. [216] However, radiation is normally avoided during pregnancy, especially if the fetal dose might exceed 100 cGy. In some cases, some or all treatments are postponed until after birth if the cancer is diagnosed late in the pregnancy. Early deliveries to speed the start of treatment are not uncommon. Surgery is generally considered safe during pregnancy, but some other treatments, especially certain chemotherapy drugs given during the first trimester, increase the risk of birth defects and pregnancy loss (spontaneous abortions and stillbirths). [216] Elective abortions are not required and do not improve the likelihood of the mother surviving or being cured. [216]

Radiation treatments may interfere with the mother's ability to breastfeed her baby because it reduces the ability of that breast to produce milk and increases the risk of mastitis. Also, when chemotherapy is being given after birth, many of the drugs pass through breast milk to the baby, which could harm the baby. [216]

Regarding future pregnancy among breast cancer survivors, there is often fear of cancer recurrence. [217] On the other hand, many still regard pregnancy and parenthood to represent normality, happiness and life fulfillment. [217]


Birth control

In breast cancer survivors, non-hormonal birth control methods such as the copper intrauterine device (IUD) should be used as first-line options. [218] Progestogen-based methods such as depot medroxyprogesterone acetate, IUD with progestogen or progestogen only pills have a poorly investigated but possible increased risk of cancer recurrence, but may be used if positive effects outweigh this possible risk. [219]

Menopausal hormone replacement

In breast cancer survivors, it is recommended to first consider non-hormonal options for menopausal effects, such as bisphosphonates or SERMs for osteoporosis, and vaginal estrogen for local symptoms. Observational studies of systemic HRT after breast cancer are generally reassuring. If hormone replacement is necessary after breast cancer, estrogen-only therapy or estrogen therapy with an IUD with progestogen may be safer options than combined systemic therapy. [220]


Treatments are being evaluated in clinical trials. This includes individual drugs, combinations of drugs, and surgical and radiation techniques Investigations include new types of targeted therapy, [221] cancer vaccines, oncolytic virotherapy, [222] gene therapy [223] [224] and immunotherapy. [225]

The latest research is reported annually at scientific meetings such as that of the American Society of Clinical Oncology, San Antonio Breast Cancer Symposium, [226] and the St. Gallen Oncology Conference in St. Gallen, Switzerland. [227] These studies are reviewed by professional societies and other organizations, and formulated into guidelines for specific treatment groups and risk category.

Fenretinide, a retinoid, is also being studied as a way to reduce the risk of breast cancer. [228] [229] In particular, combinations of ribociclib plus endocrine therapy have been the subject of clinical trials. [230]

A 2019 review found moderate certainty evidence that giving people antibiotics before breast cancer surgery helped to prevent surgical site infection (SSI). Further study is required to determine the most effective antibiotic protocol and use in women undergoing immediate breast reconstruction. [231]


As of 2014 cryoablation is being studied to see if it could be a substitute for a lumpectomy in small cancers. [232] There is tentative evidence in those with tumors less than 2 centimeters across. [233] It may also be used in those in who surgery is not possible. [233] Another review states that cryoablation looks promising for early breast cancer of small size. [234]

Breast cancer cell lines

Part of the current knowledge on breast carcinomas is based on in vivo and in vitro studies performed with cell lines derived from breast cancers. These provide an unlimited source of homogenous self-replicating material, free of contaminating stromal cells, and often easily cultured in simple standard media. The first breast cancer cell line described, BT-20, was established in 1958. Since then, and despite sustained work in this area, the number of permanent lines obtained has been strikingly low (about 100). Indeed, attempts to culture breast cancer cell lines from primary tumors have been largely unsuccessful. This poor efficiency was often due to technical difficulties associated with the extraction of viable tumor cells from their surrounding stroma. Most of the available breast cancer cell lines issued from metastatic tumors, mainly from pleural effusions. Effusions provided generally large numbers of dissociated, viable tumor cells with little or no contamination by fibroblasts and other tumor stroma cells. Many of the currently used BCC lines were established in the late 1970s. A very few of them, namely MCF-7, T-47D, MDA-MB-231 and SK-BR-3, account for more than two-thirds of all abstracts reporting studies on mentioned breast cancer cell lines, as concluded from a Medline-based survey.

Molecular markers

Metabolic markers

Clinically, the most useful metabolic markers in breast cancer are the estrogen and progesterone receptors that are used to predict response to hormone therapy. New or potentially new markers for breast cancer include BRCA1 and BRCA2 [235] to identify people at high risk of developing breast cancer, HER-2,[ medical citation needed ] and SCD1, for predicting response to therapeutic regimens, and urokinase plasminogen activator, PA1-1 and SCD1 for assessing prognosis.[ medical citation needed ]

Other animals

See also

Related Research Articles

<span class="mw-page-title-main">Mastectomy</span> Surgical removal of one or both breasts

Mastectomy is the medical term for the surgical removal of one or both breasts, partially or completely. A mastectomy is usually carried out to treat breast cancer. In some cases, women believed to be at high risk of breast cancer have the operation as a preventive measure. Alternatively, some women can choose to have a wide local excision, also known as a lumpectomy, an operation in which a small volume of breast tissue containing the tumor and a surrounding margin of healthy tissue is removed to conserve the breast. Both mastectomy and lumpectomy are referred to as "local therapies" for breast cancer, targeting the area of the tumor, as opposed to systemic therapies, such as chemotherapy, hormonal therapy, or immunotherapy.

<span class="mw-page-title-main">Endometrial cancer</span> Uterine cancer that is located in tissues lining the uterus

Endometrial cancer is a cancer that arises from the endometrium. It is the result of the abnormal growth of cells that have the ability to invade or spread to other parts of the body. The first sign is most often vaginal bleeding not associated with a menstrual period. Other symptoms include pain with urination, pain during sexual intercourse, or pelvic pain. Endometrial cancer occurs most commonly after menopause.

<span class="mw-page-title-main">Ovarian cancer</span> Cancer originating in or on the ovary

Ovarian cancer is a cancerous tumor of an ovary. It may originate from the ovary itself or more commonly from communicating nearby structures such as fallopian tubes or the inner lining of the abdomen. The ovary is made up of three different cell types including epithelial cells, germ cells, and stromal cells. When these cells become abnormal, they have the ability to divide and form tumors. These cells can also invade or spread to other parts of the body. When this process begins, there may be no or only vague symptoms. Symptoms become more noticeable as the cancer progresses. These symptoms may include bloating, vaginal bleeding, pelvic pain, abdominal swelling, constipation, and loss of appetite, among others. Common areas to which the cancer may spread include the lining of the abdomen, lymph nodes, lungs, and liver.

Inflammatory breast cancer (IBC) is one of the most aggressive types of breast cancer. It can occur in women of any age. It is referred to as "inflammatory" due to its frequent presentation with symptoms resembling a skin inflammation, such as erysipelas.

This is a list of terms related to oncology. The original source for this list was the US National Cancer Institute's public domain Dictionary of Cancer Terms.

<span class="mw-page-title-main">Lumpectomy</span> Limited surgical removal of breast tissue

Lumpectomy is a surgical removal of a discrete portion or "lump" of breast tissue, usually in the treatment of a malignant tumor or breast cancer. It is considered a viable breast conservation therapy, as the amount of tissue removed is limited compared to a full-breast mastectomy, and thus may have physical and emotional advantages over more disfiguring treatment. Sometimes a lumpectomy may be used to either confirm or rule out that cancer has actually been detected. A lumpectomy is usually recommended to patients whose cancer has been detected early and who do not have enlarged tumors. Although a lumpectomy is used to allow for most of the breast to remain intact, the procedure may result in adverse affects that can include sensitivity and result in scar tissue, pain, and possible disfiguration of the breast if the lump taken out is significant. According to National Comprehensive Cancer Network guidelines, lumpectomy may be performed for ductal carcinoma in situ (DCIS), invasive ductal carcinoma, or other conditions.

<span class="mw-page-title-main">Invasive carcinoma of no special type</span> Medical condition

Invasive carcinoma of no special type, invasive breast carcinoma of no special type (IBC-NST), invasive ductal carcinoma (IDC), infiltrating ductal carcinoma (IDC) or invasive ductal carcinoma, not otherwise specified (NOS) is a disease. For international audiences this article will use "invasive carcinoma NST" because it is the preferred term of the World Health Organization (WHO).

Adjuvant therapy, also known as adjunct therapy, adjuvant care, or augmentation therapy, is a therapy that is given in addition to the primary or initial therapy to maximize its effectiveness. The surgeries and complex treatment regimens used in cancer therapy have led the term to be used mainly to describe adjuvant cancer treatments. An example of such adjuvant therapy is the additional treatment usually given after surgery where all detectable disease has been removed, but where there remains a statistical risk of relapse due to the presence of undetected disease. If known disease is left behind following surgery, then further treatment is not technically adjuvant.

MammaPrint is a prognostic and predictive diagnostic test for early stage breast cancer patients that assess the risk that a tumor will metastasize to other parts of the body. It gives a binary result, high-risk or low-risk classification, and helps physicians determine whether or not a patient will benefit from chemotherapy. Women with a low risk result can safely forego chemotherapy without decreasing likelihood of disease free survival. MammaPrint is part of the personalized medicine portfolio marketed by Agendia.

Ductal carcinoma <i>in situ</i> Pre-cancerous breast lesion

Ductal carcinoma in situ (DCIS), also known as intraductal carcinoma, is a pre-cancerous or non-invasive cancerous lesion of the breast. DCIS is classified as Stage 0. It rarely produces symptoms or a breast lump that can be felt, typically being detected through screening mammography. It has been diagnosed in a significant percentage of men.

Triple-negative breast cancer (TNBC) is any breast cancer that either lacks or shows low levels of estrogen receptor (ER), progesterone receptor (PR) and human epidermal growth factor receptor 2 (HER2) overexpression and/or gene amplification. Triple-negative is sometimes used as a surrogate term for basal-like.

Breast cancer management takes different approaches depending on physical and biological characteristics of the disease, as well as the age, over-all health and personal preferences of the patient. Treatment types can be classified into local therapy and systemic treatment. Local therapy is most efficacious in early stage breast cancer, while systemic therapy is generally justified in advanced and metastatic disease, or in diseases with specific phenotypes.

<span class="mw-page-title-main">Medullary breast carcinoma</span> Rare type of breast cancer

Medullary breast carcinoma is a rare type of breast cancer that is characterized as a relatively circumscribed tumor with pushing, rather than infiltrating, margins. It is histologically characterized as poorly differentiated cells with abundant cytoplasm and pleomorphic high grade vesicular nuclei. It involves lymphocytic infiltration in and around the tumor and can appear to be brown in appearance with necrosis and hemorrhage. Prognosis is measured through staging but can often be treated successfully and has a better prognosis than other infiltrating breast carcinomas.

Metaplastic carcinoma, otherwise known as metaplastic breast cancer (MBC), is a heterogeneous group of cancers that exhibit varied patterns of metaplasia and differentiation along multiple cell lines. This rare and aggressive form of breast cancer is characterized as being composed of a mixed group of neoplasms containing both glandular and non-glandular patterns with epithelial and/or mesenchymal components. It accounts for fewer than 1% of all breast cancer diagnoses. It is most closely associated with invasive ductal carcinoma of no special type (IDC), and shares similar treatment approaches. Relative to IDC, MBC generally has higher histological grade and larger tumor size at time of diagnosis, with a lower incidence of axillary lymph node involvement. MBC tumors are typically estrogen receptor (ER), progesterone receptor (PR), and human epidermal growth factor-2 (HER-2) negative, meaning hormone therapy is generally not an effective treatment option, which correlates to a relatively poor prognosis. MBC was first recognized as a distinct pathological entity in 2000 by the World Health Organization.

Breast cancer classification divides breast cancer into categories according to different schemes criteria and serving a different purpose. The major categories are the histopathological type, the grade of the tumor, the stage of the tumor, and the expression of proteins and genes. As knowledge of cancer cell biology develops these classifications are updated.

<span class="mw-page-title-main">Male breast cancer</span> Medical condition

Male breast cancer (MBC) is a cancer in males that originates in their breasts. Males account for less than 1% of new breast cancers with about 20,000 new cases being diagnosed worldwide every year. Its incidence rates in males vs. females are, respectively, 0.4 and 66.7 per 100,000 person-years. The worldwide incidences of male as well as female breast cancers have been increasing over the last few decades. Currently, one of every 800 men are estimated to develop this cancer during their lifetimes.

Mammary secretory carcinoma (MSC), also termed secretory carcinoma of the breast, is a rare form of the breast cancers. MSC usually affects women but in a significant percentage of cases also occurs in men and children. Indeed, McDvitt and Stewart first described MSC in 1966 and termed it juvenile breast carcinoma because an increased number of cases were at that time diagnosed in juvenile females. MSC is the most common form of breast cancer in children, representing 80% of childhood breast cancers, although it accounts for less than 0.15% of all breast cancers.

Papillary carcinomas of the breast (PCB), also termed malignant papillary carcinomas of the breast, are rare forms of the breast cancers. The World Health Organization (2019) classified papillary neoplasms of the breast into 5 types: intraductal papilloma, papillary ductal carcinoma in situ (PDCIS), encapsulated papillary carcinoma (EPC), solid-papillary carcinoma (SPC), and invasive papillary carcinoma (IPC). The latter four carcinomas are considered here; intraductal papilloma is a benign neoplasm. The World Health Organization regarded solid papillary carcinoma as having two subtypes: in situ and invasive SPC.

<span class="mw-page-title-main">Invasive cribriform carcinoma of the breast</span> Medical condition

Invasive cribriform carcinoma of the breast (ICCB), also termed invasive cribriform carcinoma, is a rare type of breast cancer that accounts for 0.3% to 0.6% of all carcinomas in the breast. It originates in a lactiferous duct as opposed to the lobules that form the alveoli in the breasts' mammary glands. ICCB was first described by Dixon and colleagues in 1983 as a tumor that on microscopic histopathological inspection had a cribriform pattern, i.e. a tissue pattern consisting of numerous "Swiss cheese"-like open spaces and/or sieve-like small holes. The latest edition (2019) of the World Health Organization (2019) termed these lesions invasive cribriform carcinomas indicating that by definition they must have a component that invades out of their ducts of origin into adjacent tissues. In situ ductal cancers that have a cribriform histopathology are regarded as belonging to the group of ductal carcinoma in situ tumors.

<span class="mw-page-title-main">Pure apocrine carcinoma of the breast</span> Medical condition

Pure apocrine carcinoma of the breast (PACB) is a rare carcinoma derived from the epithelial cells in the lactiferous ducts of the mammary gland. The mammary gland is an apocrine gland. Its lactiferous ducts have two layers of epithelial cells, a luminal layer which faces the duct's lumen and a basal layer which lies beneath the luminal layer. There are at least four subtypes of epithelial cells in these ducts: luminal progenitor cells and luminal mature cells which reside in the luminal layer and mammary stem cells and basal cells which reside in the basal layer. Examination of the genes expressed in PACB cancer cells indicate that most of these tumors consist of cells derived from luminal cells but a minority of these tumors consist of cells derived from basal cells.


  1. 1 2 3 4 5 6 7 8 9 10 11 12 13 "Breast Cancer Treatment (PDQ®)". NCI. 23 May 2014. Archived from the original on 5 July 2014. Retrieved 29 June 2014.
  2. 1 2 3 4 5 6 7 8 World Cancer Report 2014. World Health Organization. 2014. pp. Chapter 5.2. ISBN   978-92-832-0429-9.
  3. "Klinefelter Syndrome". Eunice Kennedy Shriver National Institute of Child Health and Human Development. 24 May 2007. Archived from the original on 27 November 2012.
  4. 1 2 "SEER Stat Fact Sheets: Breast Cancer". NCI. Archived from the original on 3 July 2014. Retrieved 18 June 2014.
  5. 1 2 "Cancer Survival in England: Patients Diagnosed 2007–2011 and Followed up to 2012" (PDF). Office for National Statistics. 29 October 2013. Archived (PDF) from the original on 29 November 2014. Retrieved 29 June 2014.
  6. 1 2 Sung H, Ferlay J, Siegel RL, Laversanne M, Soerjomataram I, Jemal A, et al. (May 2021). "Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries". CA: A Cancer Journal for Clinicians. 71 (3): 209–249. doi: 10.3322/caac.21660 . PMID   33538338. S2CID   231804598.
  7. "Breast Cancer". NCI. January 1980. Archived from the original on 25 June 2014. Retrieved 29 June 2014.
  8. Saunders C, Jassal S (2009). Breast cancer (1. ed.). Oxford: Oxford University Press. p. Chapter 13. ISBN   978-0-19-955869-8. Archived from the original on 25 October 2015.
  9. Fakhri N, Chad MA, Lahkim M, Houari A, Dehbi H, Belmouden A, et al. (September 2022). "Risk factors for breast cancer in women: an update review". Medical Oncology. 39 (12): 197. doi:10.1007/s12032-022-01804-x. PMID   36071255. S2CID   252113509.
  10. Gøtzsche PC, Jørgensen KJ (June 2013). "Screening for breast cancer with mammography". The Cochrane Database of Systematic Reviews. 2013 (6): CD001877. doi:10.1002/14651858.CD001877.pub5. PMC   6464778 . PMID   23737396.
  11. Nelson HD, Tyne K, Naik A, Bougatsos C, Chan B, Nygren P, et al. (November 2009). "Screening for Breast Cancer: Systematic Evidence Review Update for the US Preventive Services Task Force [Internet]". U.S. Preventive Services Task Force Evidence Syntheses. Rockville, MD: Agency for Healthcare Research and Quality. PMID   20722173. Report No.: 10-05142-EF-1.
  12. 1 2 Siu AL (February 2016). "Screening for Breast Cancer: U.S. Preventive Services Task Force Recommendation Statement". Annals of Internal Medicine. 164 (4): 279–96. doi: 10.7326/M15-2886 . PMID   26757170.
  13. "Five Things Physicians and Patients Should Question". Choosing Wisely: an initiative of the ABIM Foundation . American College of Surgeons. September 2013. Archived from the original on 27 October 2013. Retrieved 2 January 2013.
  14. 1 2 3 4 "Breast Cancer Treatment (PDQ®)". NCI. 26 June 2014. Archived from the original on 5 July 2014. Retrieved 29 June 2014.
  15. 1 2 "World Cancer Report" (PDF). International Agency for Research on Cancer. 2008. Archived from the original (PDF) on 20 July 2011. Retrieved 26 February 2011.
  16. World Cancer Report 2014. World Health Organization. 2014. pp. Chapter 1.1. ISBN   978-92-832-0429-9.
  17. Bray F, Ferlay J, Soerjomataram I, Siegel RL, Torre LA, Jemal A (November 2018). "Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries". CA: A Cancer Journal for Clinicians. 68 (6): 394–424. doi: 10.3322/caac.21492 . PMID   30207593. S2CID   52188256.
  18. "Male Breast Cancer Treatment". . 2014. Archived from the original on 4 July 2014. Retrieved 29 June 2014.
  19. "Breast Cancer Screening Guidelines for Transgender People".
  20. 1 2 Hayes & Lippman 2022, "Evaluation of Breast Masses".
  21. 1 2 3 "Breast Cancer Signs and Symptoms". American Cancer Society. 14 January 2022. Retrieved 25 March 2024.
  22. "Inflammatory Breast Cancer". American Cancer Society. 1 March 2023. Retrieved 28 March 2024.
  23. "Paget's disease of the breast". Cancer Research UK. 20 June 2023. Retrieved 25 March 2024.
  24. Lacroix M (December 2006). "Significance, detection and markers of disseminated breast cancer cells". Endocrine-Related Cancer. 13 (4): 1033–67. doi: 10.1677/ERC-06-0001 . PMID   17158753.
  25. "Stage 4 :: The National Breast Cancer Foundation". National Breast Cancer Foundation. Archived from the original on 1 February 2021. Retrieved 29 April 2019.
  26. National Cancer Institute (1 September 2004). "Metastatic Cancer: Questions and Answers". Archived from the original on 27 August 2008. Retrieved 6 February 2008.
  27. Perera N, Fernando N, Perera R (March 2020). "Metastatic breast cancer spread to peripancreatic lymph nodes causing biliary obstruction". The Breast Journal. 26 (3): 511–13. doi: 10.1111/tbj.13531 . PMID   31538691.
  28. Interpreting Signs and Symptoms. Lippincott Williams & Wilkins. 2007. pp. 99–. ISBN   978-1-58255-668-0.
  29. Merck Manual of Diagnosis and Therapy (February 2003). "Breast Disorders: Overview of Breast Disorders". Archived from the original on 3 October 2011. Retrieved 5 February 2008.
  30. 1 2 3 Hayes & Lippman 2022, "Clinical, Hormonal, and other Nongenetic Risk Factors".
  31. Collaborative Group on Hormonal Factors in Breast Cancer (September 2019). "Type and timing of menopausal hormone therapy and breast cancer risk: individual participant meta-analysis of the worldwide epidemiological evidence". Lancet. 394 (10204): 1159–1168. doi:10.1016/S0140-6736(19)31709-X. PMC   6891893 . PMID   31474332.
  32. 1 2 "Risk of breast cancer with HRT depends on therapy type and duration". NIHR Evidence. National Institute for Health and Care Research. 20 December 2021. doi:10.3310/alert_48575. Archived from the original on 26 October 2023. Retrieved 26 October 2023.
  33. 1 2 Vinogradova Y, Coupland C, Hippisley-Cox J (October 2020). "Use of hormone replacement therapy and risk of breast cancer: nested case-control studies using the QResearch and CPRD databases". BMJ. 371: m3873. doi:10.1136/bmj.m3873. PMC   7592147 . PMID   33115755.
  34. Russo J, Russo IH (August 1980). "Susceptibility of the mammary gland to carcinogenesis. II. Pregnancy interruption as a risk factor in tumor incidence". The American Journal of Pathology. 100 (2): 497–512. PMC   1903536 . PMID   6773421. In contrast, abortion is associated with increased risk of carcinomas of the breast. The explanation for these epidemiologic findings is not known, but the parallelism between the DMBA-induced rat mammary carcinoma model and the human situation is striking. ... Abortion would interrupt this process, leaving in the gland undifferentiated structures like those observed in the rat mammary gland, which could render the gland again susceptible to carcinogenesis.
  35. Beral V, Bull D, Doll R, Peto R, Reeves G (March 2004). "Breast cancer and abortion: collaborative reanalysis of data from 53 epidemiological studies, including 83?000 women with breast cancer from 16 countries". Lancet. 363 (9414): 1007–16. doi:10.1016/S0140-6736(04)15835-2. PMID   15051280. S2CID   20751083.
  36. Kanadys W, Barańska A, Malm M, Błaszczuk A, Polz-Dacewicz M, Janiszewska M, et al. (April 2021). "Use of Oral Contraceptives as a Potential Risk Factor for Breast Cancer: A Systematic Review and Meta-Analysis of Case-Control Studies Up to 2010". International Journal of Environmental Research and Public Health. 18 (9): 4638. doi: 10.3390/ijerph18094638 . PMC   8123798 . PMID   33925599.
  37. Chelmow D, Pearlman MD, Young A, Bozzuto L, Dayaratna S, Jeudy M, et al. (June 2020). "Executive Summary of the Early-Onset Breast Cancer Evidence Review Conference". Obstetrics and Gynecology. 135 (6): 1457–1478. doi:10.1097/AOG.0000000000003889. PMC   7253192 . PMID   32459439.
  38. Gaffield ME, Culwell KR, Ravi A (October 2009). "Oral contraceptives and family history of breast cancer". Contraception. 80 (4): 372–380. doi:10.1016/j.contraception.2009.04.010. PMID   19751860.
  39. 1 2 Choi YJ, Myung SK, Lee JH (April 2018). "Light Alcohol Drinking and Risk of Cancer: A Meta-Analysis of Cohort Studies". Cancer Research and Treatment. 50 (2): 474–487. doi:10.4143/crt.2017.094. PMC   5912140 . PMID   28546524.
  40. Bagnardi V, Rota M, Botteri E, Tramacere I, Islami F, Fedirko V, et al. (February 2015). "Alcohol consumption and site-specific cancer risk: a comprehensive dose-response meta-analysis". British Journal of Cancer. 112 (3): 580–593. doi:10.1038/bjc.2014.579. PMC   4453639 . PMID   25422909.
  41. 1 2 Shield KD, Soerjomataram I, Rehm J (June 2016). "Alcohol Use and Breast Cancer: A Critical Review". Alcoholism: Clinical and Experimental Research. 40 (6): 1166–1181. doi:10.1111/acer.13071. PMID   27130687. All levels of evidence showed a risk relationship between alcohol consumption and the risk of breast cancer, even at low levels of consumption.
  42. McDonald JA, Goyal A, Terry MB (September 2013). "Alcohol Intake and Breast Cancer Risk: Weighing the Overall Evidence". Current Breast Cancer Reports. 5 (3): 208–221. doi:10.1007/s12609-013-0114-z. PMC   3832299 . PMID   24265860.
  43. 1 2 "Why we need to understand breast cancer risk". NIHR Evidence (Plain English summary). National Institute for Health and Care Research. 5 October 2023. doi:10.3310/nihrevidence_60242. S2CID   263690185. Archived from the original on 26 October 2023. Retrieved 26 October 2023.
  44. Pearson-Stuttard J, Zhou B, Kontis V, Bentham J, Gunter MJ, Ezzati M (June 2018). "Worldwide burden of cancer attributable to diabetes and high body-mass index: a comparative risk assessment". The Lancet. Diabetes & Endocrinology. 6 (6): e6–e15. doi:10.1016/S2213-8587(18)30150-5. PMC   5982644 . PMID   29803268.
  45. "Lifestyle-related Breast Cancer Risk Factors". American Cancer Society . Archived from the original on 27 July 2020. Retrieved 18 April 2018.
  46. Blackburn GL, Wang KA (September 2007). "Dietary fat reduction and breast cancer outcome: results from the Women's Intervention Nutrition Study (WINS)". The American Journal of Clinical Nutrition. 86 (3): s878-81. doi: 10.1093/ajcn/86.3.878S . PMID   18265482.
  47. "Weight link to breast cancer risk". BBC News. 12 July 2006. Archived from the original on 13 March 2007.
  48. Kaiser J (November 2013). "Cancer. Cholesterol forges link between obesity and breast cancer". Science. 342 (6162): 1028. doi:10.1126/science.342.6162.1028. PMID   24288308.
  49. Aceves C, Anguiano B, Delgado G (April 2005). "Is iodine a gatekeeper of the integrity of the mammary gland?". Journal of Mammary Gland Biology and Neoplasia. 10 (2): 189–96. doi:10.1007/s10911-005-5401-5. PMID   16025225. S2CID   16838840.
  50. 1 2 Johnson KC, Miller AB, Collishaw NE, Palmer JR, Hammond SK, Salmon AG, et al. (January 2011). "Active smoking and secondhand smoke increase breast cancer risk: the report of the Canadian Expert Panel on Tobacco Smoke and Breast Cancer Risk (2009)". Tobacco Control. 20 (1): e2. doi:10.1136/tc.2010.035931. PMID   21148114. S2CID   448229.
  51. Lee IM, Shiroma EJ, Lobelo F, Puska P, Blair SN, Katzmarzyk PT (July 2012). "Effect of physical inactivity on major non-communicable diseases worldwide: an analysis of burden of disease and life expectancy". Lancet. 380 (9838): 219–29. doi:10.1016/S0140-6736(12)61031-9. PMC   3645500 . PMID   22818936.
  52. Biswas A, Oh PI, Faulkner GE, Bajaj RR, Silver MA, Mitchell MS, et al. (January 2015). "Sedentary time and its association with risk for disease incidence, mortality, and hospitalization in adults: a systematic review and meta-analysis". Annals of Internal Medicine. 162 (2): 123–32. doi:10.7326/M14-1651. PMID   25599350. S2CID   7256176.
  53. 1 2 Zhang YB, Pan XF, Chen J, Cao A, Zhang YG, Xia L, et al. (March 2020). "Combined lifestyle factors, incident cancer, and cancer mortality: a systematic review and meta-analysis of prospective cohort studies". British Journal of Cancer. 122 (7): 1085–1093. doi:10.1038/s41416-020-0741-x. PMC   7109112 . PMID   32037402.
  54. "Breast Cancer Facts & Figures 2005–2006" (PDF). American Cancer Society. 2005. Archived from the original (PDF) on 13 June 2007. Retrieved 26 April 2007.
  55. Wang XS, Armstrong ME, Cairns BJ, Key TJ, Travis RC (March 2011). "Shift work and chronic disease: the epidemiological evidence". Occupational Medicine. 61 (2): 78–89. doi:10.1093/occmed/kqr001. PMC   3045028 . PMID   21355031.
  56. Marinac CR, Nelson SH, Breen CI, Hartman SJ, Natarajan L, Pierce JP, et al. (August 2016). "Prolonged Nightly Fasting and Breast Cancer Prognosis". JAMA Oncology. 2 (8): 1049–55. doi:10.1001/jamaoncol.2016.0164. PMC   4982776 . PMID   27032109.
  57. Brody JG, Rudel RA, Michels KB, Moysich KB, Bernstein L, Attfield KR, et al. (June 2007). "Environmental pollutants, diet, physical activity, body size, and breast cancer: where do we stand in research to identify opportunities for prevention?". Cancer. 109 (12 Suppl): 2627–34. doi:10.1002/cncr.22656. PMID   17503444. S2CID   34880415.
  58. Hendrick RE (October 2010). "Radiation doses and cancer risks from breast imaging studies". Radiology. 257 (1): 246–53. doi: 10.1148/radiol.10100570 . PMID   20736332.
  59. 1 2 3 4 Loibl et al. 2021, "Epidemiology and risk factors".
  60. 1 2 3 4 Hayes & Lippman 2022, "Inherited germline susceptibility factors".
  61. Collaborative Group on Hormonal Factors in Breast Cancer (October 2001). "Familial breast cancer: collaborative reanalysis of individual data from 52 epidemiological studies including 58,209 women with breast cancer and 101,986 women without the disease". Lancet. 358 (9291): 1389–99. doi:10.1016/S0140-6736(01)06524-2. PMID   11705483. S2CID   24278814.
  62. "CDC – What Are the Risk Factors for Breast Cancer?". 14 December 2018. Archived from the original on 13 August 2020. Retrieved 29 April 2019.
  63. Tian JM, Ran B, Zhang CL, Yan DM, Li XH (January 2018). "Estrogen and progesterone promote breast cancer cell proliferation by inducing cyclin G1 expression". Brazilian Journal of Medical and Biological Research. 51 (3): 1–7. doi:10.1590/1414-431X20175612. PMC   5912097 . PMID   29513878. Archived from the original on 14 May 2017. Retrieved 29 April 2019.
  64. "Understanding Breast Changes – National Cancer Institute". Archived from the original on 27 May 2010.
  65. "Breast Cancer Treatment". National Cancer Institute. January 1980. Archived from the original on 25 April 2015.
  66. Afonso N, Bouwman D (August 2008). "Lobular carcinoma in situ". European Journal of Cancer Prevention. 17 (4): 312–6. doi:10.1097/CEJ.0b013e3282f75e5d. PMID   18562954. S2CID   388045.
  67. Anothaisintawee T, Wiratkapun C, Lerdsitthichai P, Kasamesup V, Wongwaisayawan S, Srinakarin J, et al. (September 2013). "Risk factors of breast cancer: a systematic review and meta-analysis". Asia-Pacific Journal of Public Health. 25 (5): 368–87. doi:10.1177/1010539513488795. PMID   23709491. S2CID   206616972.
  68. Böhm I (June 2011). "Breast cancer in lupus". Breast. 20 (3): 288–90. doi: 10.1016/j.breast.2010.12.005 . PMID   21237645.
  69. Williams C, Lin CY (November 2013). "Oestrogen receptors in breast cancer: basic mechanisms and clinical implications". ecancermedicalscience. 7: 370. doi:10.3332/ecancer.2013.370. PMC   3816846 . PMID   24222786.
  70. Levin ER, Pietras RJ (April 2008). "Estrogen receptors outside the nucleus in breast cancer". Breast Cancer Research and Treatment. 108 (3): 351–361. doi:10.1007/s10549-007-9618-4. PMID   17592774. S2CID   11394158.
  71. Lee A, Arteaga C (14 December 2009). "32nd Annual CTRC-AACR San Antonio Breast Cancer Symposium" (PDF). Sunday Morning Year-End Review. Archived from the original (PDF) on 13 August 2013.
  72. Cavalieri E, Chakravarti D, Guttenplan J, Hart E, Ingle J, Jankowiak R, et al. (August 2006). "Catechol estrogen quinones as initiators of breast and other human cancers: implications for biomarkers of susceptibility and cancer prevention". Biochimica et Biophysica Acta (BBA) - Reviews on Cancer. 1766 (1): 63–78. doi:10.1016/j.bbcan.2006.03.001. PMID   16675129.
  73. Filardo EJ (February 2018). "A role for G-protein coupled estrogen receptor (GPER) in estrogen-induced carcinogenesis: Dysregulated glandular homeostasis, survival and metastasis". The Journal of Steroid Biochemistry and Molecular Biology. 176: 38–48. doi:10.1016/j.jsbmb.2017.05.005. PMID   28595943. S2CID   19644829.
  74. Haslam SZ, Woodward TL (June 2003). "Host microenvironment in breast cancer development: epithelial-cell-stromal-cell interactions and steroid hormone action in normal and cancerous mammary gland". Breast Cancer Research. 5 (4): 208–15. doi: 10.1186/bcr615 . PMC   165024 . PMID   12817994.
  75. Wiseman BS, Werb Z (May 2002). "Stromal effects on mammary gland development and breast cancer". Science. 296 (5570): 1046–9. Bibcode:2002Sci...296.1046W. doi:10.1126/science.1067431. PMC   2788989 . PMID   12004111.
  76. Jardé T, Perrier S, Vasson MP, Caldefie-Chézet F (January 2011). "Molecular mechanisms of leptin and adiponectin in breast cancer". European Journal of Cancer. 47 (1): 33–43. doi:10.1016/j.ejca.2010.09.005. PMID   20889333.
  77. Patel KJ, Yu VP, Lee H, Corcoran A, Thistlethwaite FC, Evans MJ, et al. (February 1998). "Involvement of Brca2 in DNA repair". Molecular Cell. 1 (3): 347–57. doi: 10.1016/S1097-2765(00)80035-0 . PMID   9660919.
  78. Marietta C, Thompson LH, Lamerdin JE, Brooks PJ (May 2009). "Acetaldehyde stimulates FANCD2 monoubiquitination, H2AX phosphorylation, and BRCA1 phosphorylation in human cells in vitro: implications for alcohol-related carcinogenesis". Mutation Research. 664 (1–2): 77–83. doi:10.1016/j.mrfmmm.2009.03.011. PMC   2807731 . PMID   19428384.
  79. Theruvathu JA, Jaruga P, Nath RG, Dizdaroglu M, Brooks PJ (2005). "Polyamines stimulate the formation of mutagenic 1,N2-propanodeoxyguanosine adducts from acetaldehyde". Nucleic Acids Research. 33 (11): 3513–20. doi:10.1093/nar/gki661. PMC   1156964 . PMID   15972793.
  80. Kouros-Mehr H, Kim JW, Bechis SK, Werb Z (April 2008). "GATA-3 and the regulation of the mammary luminal cell fate". Current Opinion in Cell Biology. 20 (2): 164–70. doi:10.1016/ PMC   2397451 . PMID   18358709.
  81. 1 2 "Breast Cancer Screening PDQ – Patient Version". National Cancer Institute. 26 June 2023. Retrieved 5 January 2024.
  82. "Findings on a Mammogram and Mammogram Results". Susan G. Komen Foundation. 30 November 2022. Retrieved 5 January 2024.
  83. Nielsen & Narayan 2023, "Interpretation of a Mammogram".
  84. Metaxa, Healy & O'Keeffe 2019, "Introduction".
  85. "Understanding Your Mammogram Report". American Cancer Society. 14 January 2022. Retrieved 8 January 2024.
  86. "Breast Density and Your Mammogram Report". American Cancer Society. 28 March 2023. Retrieved 8 January 2024.
  87. Nielsen & Narayan 2023, "Implications of Breast Density".
  88. 1 2 Harbeck et al. 2019, "Screening".
  89. Loibl et al. 2021, "Screening".
  90. 1 2 Hayes & Lippman 2022, "Screening for Breast Cancer".
  91. Rahman & Helvie 2022, "Table 1".
  92. "Breast Cancer Screening (PDQ) - Health Professional Version". National Cancer Institute. 7 June 2023. Retrieved 10 January 2024.
  93. Menes et al. 2021, "Abstract".
  94. Qaseem A, Lin JS, Mustafa RA, Horwitch CA, Wilt TJ (April 2019). "Screening for Breast Cancer in Average-Risk Women: A Guidance Statement From the American College of Physicians". Annals of Internal Medicine. 170 (8): 547–560. doi: 10.7326/M18-2147 . PMID   30959525.
  95. Biesheuvel C, Weigel S, Heindel W (2011). "Mammography Screening: Evidence, History and Current Practice in Germany and Other European Countries". Breast Care. 6 (2): 104–109. doi:10.1159/000327493. PMC   3104900 . PMID   21673820.
  96. Schünemann HJ, Lerda D, Quinn C, Follmann M, Alonso-Coello P, Rossi PG, et al. (January 2020). "Breast Cancer Screening and Diagnosis: A Synopsis of the European Breast Guidelines". Annals of Internal Medicine. 172 (1): 46–56. doi: 10.7326/M19-2125 . PMID   31766052.
  97. Tonelli M, Connor Gorber S, Joffres M, Dickinson J, Singh H, Lewin G, et al. (November 2011). "Recommendations on screening for breast cancer in average-risk women aged 40–74 years". CMAJ. 183 (17): 1991–2001. doi:10.1503/cmaj.110334. PMC   3225421 . PMID   22106103.
  98. Moss S (August 2004). "Should women under 50 be screened for breast cancer?". British Journal of Cancer. 91 (3): 413–417. doi:10.1038/sj.bjc.6601966. PMC   2409834 . PMID   15213718.
  99. "Breast Cancer: Screening". United States Preventive Services Task Force. Archived from the original on 16 June 2013.
  100. 1 2 "Breast Biopsy". National Breast Cancer Foundation. Retrieved 10 January 2024.
  101. Harbeck et al. 2019, "Diagnostic Work-Up".
  102. 1 2 Hayes & Lippman 2022, "Pathologic Findings of the Breast".
  103. Cruz-Roa A, Gilmore H, Basavanhally A, Feldman M, Ganesan S, Shih NN, et al. (2017). "Accurate and reproducible invasive breast cancer detection in whole-slide images: A Deep Learning approach for quantifying tumor extent". Sci Rep. 7: 46450. Bibcode:2017NatSR...746450C. doi:10.1038/srep46450. PMC   5394452 . PMID   28418027.
    "This work is licensed under a Creative Commons Attribution 4.0 International License."
  104. 1 2 Hayes & Lippman 2022, "Invasive Breast Cancers".
  105. 1 2 3 Hayes & Lippman 2022, "Noninvasive Breast Neoplasms".
  106. 1 2 "Breast Cancer Grade". American Caner Society. 8 November 2021. Retrieved 13 February 2024.
  107. Harbeck et al. 2019, "Histologic Grade".
  108. Harbeck et al. 2019, "Theranostic Biomarkers".
  109. 1 2 "Breast Cancer Hormone Receptor Status". American Cancer Society. 8 November 2021. Retrieved 20 February 2024.
  110. "Breast Cancer HER2 Status". American Cancer Society. 25 August 2022. Retrieved 20 February 2024.
  111. Harbeck et al. 2019, "Lymph node status and pathological stage".
  112. AJCC Staging Manual 2017, "Rules for Classification".
  113. AJCC Staging Manual 2017, "Primary Tumor (T)".
  114. 1 2 AJCC Staging Manual 2017, "Regional Lymph Nodes – Clinical".
  115. AJCC Staging Manual 2017, "Distant Metastasis (M)".
  116. AJCC Staging Manual 2017, "AJCC Prognostic Stage Groups".
  117. 1 2 3 "Lifestyle-related Breast Cancer Risk Factors". Archived from the original on 27 July 2020. Retrieved 18 April 2018.
  118. Eliassen AH, Hankinson SE, Rosner B, Holmes MD, Willett WC (October 2010). "Physical activity and risk of breast cancer among postmenopausal women". Archives of Internal Medicine. 170 (19): 1758–64. doi:10.1001/archinternmed.2010.363. PMC   3142573 . PMID   20975025.
  119. Kyu HH, Bachman VF, Alexander LT, Mumford JE, Afshin A, Estep K, et al. (August 2016). "Physical activity and risk of breast cancer, colon cancer, diabetes, ischemic heart disease, and ischemic stroke events: systematic review and dose-response meta-analysis for the Global Burden of Disease Study 2013". BMJ. 354: i3857. doi:10.1136/bmj.i3857. PMC   4979358 . PMID   27510511.
  120. Hayes J, Richardson A, Frampton C (November 2013). "Population attributable risks for modifiable lifestyle factors and breast cancer in New Zealand women". Internal Medicine Journal. 43 (11): 1198–204. doi:10.1111/imj.12256. PMID   23910051. S2CID   23237732.
  121. "New study finds 'strong evidence' that exercise cuts breast cancer risk". belfasttelegraph. ISSN   0307-1235. Archived from the original on 7 September 2022. Retrieved 7 September 2022.
  122. Runowicz CD, Leach CR, Henry NL, Henry KS, Mackey HT, Cowens-Alvarado RL, et al. (January 2016). "American Cancer Society/American Society of Clinical Oncology Breast Cancer Survivorship Care Guideline". CA: A Cancer Journal for Clinicians. 66 (1): 43–73. doi: 10.3322/caac.21319 . hdl: 2027.42/136493 . PMID   26641959.
  123. Farvid MS, Spence ND, Holmes MD, Barnett JB (July 2020). "Fiber consumption and breast cancer incidence: A systematic review and meta-analysis of prospective studies". Cancer. 126 (13): 3061–3075. doi: 10.1002/cncr.32816 . PMID   32249416. S2CID   214809009.
  124. Farvid MS, Barnett JB, Spence ND (July 2021). "Fruit and vegetable consumption and incident breast cancer: a systematic review and meta-analysis of prospective studies". British Journal of Cancer. 125 (2): 284–298. doi:10.1038/s41416-021-01373-2. PMC   8292326 . PMID   34006925.
  125. Song JK, Bae JM (March 2013). "Citrus fruit intake and breast cancer risk: a quantitative systematic review". Journal of Breast Cancer. 16 (1): 72–6. doi:10.4048/jbc.2013.16.1.72. PMC   3625773 . PMID   23593085.
  126. Zheng JS, Hu XJ, Zhao YM, Yang J, Li D (June 2013). "Intake of fish and marine n-3 polyunsaturated fatty acids and risk of breast cancer: meta-analysis of data from 21 independent prospective cohort studies". BMJ. 346: f3706. doi: 10.1136/bmj.f3706 . PMID   23814120.
  127. Wu AH, Yu MC, Tseng CC, Pike MC (January 2008). "Epidemiology of soy exposures and breast cancer risk". British Journal of Cancer. 98 (1): 9–14. doi:10.1038/sj.bjc.6604145. PMC   2359677 . PMID   18182974.
  128. 1 2 3 Hayes & Lippman 2022, "Prevention of Breast Cancer".
  129. Carbine NE, Lostumbo L, Wallace J, Ko H (April 2018). "Risk-reducing mastectomy for the prevention of primary breast cancer". The Cochrane Database of Systematic Reviews. 4 (4): CD002748. doi:10.1002/14651858.cd002748.pub4. PMC   6494635 . PMID   29620792.
  130. "Earlier decisions on breast and ovarian surgery reduce cancer in women at high risk". NIHR Evidence (Plain English summary). National Institute for Health and Care Research. 7 December 2021. doi:10.3310/alert_48318. S2CID   263487127. Archived from the original on 27 June 2022. Retrieved 21 December 2022.
  131. Marcinkute R, Woodward ER, Gandhi A, Howell S, Crosbie EJ, Wissely J, et al. (February 2022). "Uptake and efficacy of bilateral risk reducing surgery in unaffected female BRCA1 and BRCA2 carriers". Journal of Medical Genetics. 59 (2): 133–140. doi:10.1136/jmedgenet-2020-107356. PMID   33568438. S2CID   231876899. Archived from the original on 2 February 2023. Retrieved 21 December 2022.
  132. 1 2 Nelson HD, Smith ME, Griffin JC, Fu R (April 2013). "Use of medications to reduce risk for primary breast cancer: a systematic review for the U.S. Preventive Services Task Force". Annals of Internal Medicine. 158 (8): 604–14. doi: 10.7326/0003-4819-158-8-201304160-00005 . PMID   23588749.
  133. Cuzick J, Sestak I, Bonanni B, Costantino JP, Cummings S, DeCensi A, et al. (May 2013). "Selective oestrogen receptor modulators in prevention of breast cancer: an updated meta-analysis of individual participant data". Lancet. 381 (9880): 1827–34. doi:10.1016/S0140-6736(13)60140-3. PMC   3671272 . PMID   23639488.
  134. Owens DK, Davidson KW, Krist AH, Barry MJ, Cabana M, Caughey AB, et al. (September 2019). "Medication Use to Reduce Risk of Breast Cancer: US Preventive Services Task Force Recommendation Statement". JAMA. 322 (9): 857–867. doi: 10.1001/jama.2019.11885 . PMID   31479144.
  135. Cuzick J, Sestak I, Bonanni B, Costantino JP, Cummings S, DeCensi A, et al. (May 2013). "Selective oestrogen receptor modulators in prevention of breast cancer: an updated meta-analysis of individual participant data". Lancet. 381 (9880): 1827–34. doi:10.1016/S0140-6736(13)60140-3. PMC   3671272 . PMID   23639488.
  136. Mocellin S, Goodwin A, Pasquali S (April 2019). "Risk-reducing medications for primary breast cancer: a network meta-analysis". The Cochrane Database of Systematic Reviews. 2019 (4): CD012191. doi:10.1002/14651858.cd012191.pub2. PMC   6487387 . PMID   31032883.
  137. 1 2 3 Hayes & Lippman 2022, "Local (Primary) Treatments".
  138. 1 2 3 4 "Radiation for Breast Cancer". American Cancer Society. 27 October 2021. Retrieved 12 April 2024.
  139. Leite AM, Macedo AV, Jorge AJ, Martins WA (August 2018). "Antiplatelet Therapy in Breast Cancer Patients Using Hormonal Therapy: Myths, Evidence and Potentialities – Systematic Review". Arquivos Brasileiros de Cardiologia. 111 (2): 205–212. doi:10.5935/abc.20180138. PMC   6122903 . PMID   30183988.
  140. Holmes MD, Chen WY, Li L, Hertzmark E, Spiegelman D, Hankinson SE (March 2010). "Aspirin intake and survival after breast cancer". Journal of Clinical Oncology. 28 (9): 1467–72. doi:10.1200/JCO.2009.22.7918. PMC   2849768 . PMID   20159825.
  141. Bao T, Rudek MA (2011). "The Clinical Pharmacology of Anastrozole". European Oncology & Haematology. 7 (2): 106–8. doi:10.17925/EOH.2011.07.02.106. S2CID   1802863.
  142. Burstein HJ, Temin S, Anderson H, Buchholz TA, Davidson NE, Gelmon KE, et al. (July 2014). "Adjuvant endocrine therapy for women with hormone receptor-positive breast cancer: american society of clinical oncology clinical practice guideline focused update". Journal of Clinical Oncology. 32 (21): 2255–69. doi:10.1200/JCO.2013.54.2258. PMC   4876310 . PMID   24868023.
  143. Romero SA, Young K, Hickey M, Su HI (21 December 2020). "Levonorgestrel intrauterine system for endometrial protection in women with breast cancer on adjuvant tamoxifen". Cochrane Database Syst Rev. 12 (2): CD007245. doi:10.1002/14651858.CD007245.pub4. PMC   8092675 . PMID   33348436.
  144. Early Breast Cancer Trialists' Collaborative Group (EBCTCG) (October 2015). "Aromatase inhibitors versus tamoxifen in early breast cancer: patient-level meta-analysis of the randomised trials". Lancet. 386 (10001): 1341–1352. doi: 10.1016/S0140-6736(15)61074-1 . hdl: 10044/1/32438 . PMID   26211827.
  145. Petit T, Dufour P, Tannock I (June 2011). "A critical evaluation of the role of aromatase inhibitors as adjuvant therapy for postmenopausal women with breast cancer". Endocrine-Related Cancer. 18 (3): R79-89. doi: 10.1530/ERC-10-0162 . PMID   21502311.
  146. "Treatment of metastatic breast cancer". Archived from the original on 4 September 2017. Retrieved 4 September 2017.
  147. "Combination of Ribociclib and Letrozole Is a Home Run in Advanced Breast Cancer – The ASCO Post". Archived from the original on 29 July 2020. Retrieved 31 January 2019.
  148. Jahanzeb M (August 2008). "Adjuvant trastuzumab therapy for HER2-positive breast cancer". Clinical Breast Cancer. 8 (4): 324–33. doi:10.3816/CBC.2008.n.037. PMID   18757259.
  149. "Entrez Gene: ERBB2 v-erb-b2 erythroblastic leukemia viral oncogene homolog 2, neuro/glioblastoma derived oncogene homolog (avian)". Archived from the original on 26 October 2009. Retrieved 17 November 2015.
  150. "Herceptin (trastuzumab) Adjuvant HER2+ Breast Cancer Therapy Pivotal Studies and Efficacy Data". Archived from the original on 6 April 2010. Retrieved 8 May 2010.
  151. "New ASCO Guidelines on Treating Advanced-Stage HER2-Positive Breast Cancer". 4 October 2016. Archived from the original on 27 July 2020. Retrieved 31 January 2019.
  152. Slamon DJ, Leyland-Jones B, Shak S, Fuchs H, Paton V, Bajamonde A, et al. (March 2001). "Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2". The New England Journal of Medicine. 344 (11): 783–92. doi: 10.1056/NEJM200103153441101 . PMID   11248153.
  153. "FDA approves elacestrant for ER-positive, HER2-negative, ESR1-mutated advanced or metastatic breast cancer". U.S. Food and Drug Administration (FDA). 27 January 2023. Archived from the original on 2 February 2023. Retrieved 1 February 2023.PD-icon.svg This article incorporates text from this source, which is in the public domain .
  154. "Stemline Therapeutics Inc., a wholly owned subsidiary of Menarini Group, Receives Approval from U.S. FDA for Orserdu (elacestrant) as the First and Only Treatment Specifically Indicated for Patients with ESR1 Mutations in ER+, HER2- Advanced or Metastatic Breast Cancer". Radius (Press release). 31 January 2023. Archived from the original on 2 February 2023. Retrieved 1 February 2023.
  155. "FDA approves capivasertib with fulvestrant for breast cancer". U.S. Food and Drug Administration. 16 November 2023. Archived from the original on 17 November 2023. Retrieved 17 November 2023.PD-icon.svg This article incorporates text from this source, which is in the public domain .
  156. "Oncology (Cancer) / Hematologic Malignancies Approval Notifications". U.S. Food and Drug Administration. 16 November 2023. Archived from the original on 17 November 2023. Retrieved 17 November 2023.
  157. "Truqap (capivasertib) plus Faslodex approved in the US for patients with advanced HR-positive breast cancer". AstraZeneca (Press release). 17 November 2023. Archived from the original on 17 November 2023. Retrieved 17 November 2023.
  158. Moschetti I, Cinquini M, Lambertini M, Levaggi A, Liberati A (May 2016). "Follow-up strategies for women treated for early breast cancer". The Cochrane Database of Systematic Reviews. 2016 (5): CD001768. doi:10.1002/14651858.cd001768.pub3. PMC   7073405 . PMID   27230946.
  159. Khan F, Amatya B, Ng L, Demetrios M, Zhang NY, Turner-Stokes L (December 2012). "Multidisciplinary rehabilitation for follow-up of women treated for breast cancer". The Cochrane Database of Systematic Reviews. 12 (3): CD009553. doi:10.1002/14651858.cd009553.pub2. PMC   8078577 . PMID   23235677.
  160. Lee TS, Kilbreath SL, Refshauge KM, Herbert RD, Beith JM (July 2008). "Prognosis of the upper limb following surgery and radiation for breast cancer". Breast Cancer Research and Treatment. 110 (1): 19–37. doi:10.1007/s10549-007-9710-9. PMID   17899373. S2CID   24976113.
  161. "Exercise programme improves arm function and pain after breast cancer surgery". NIHR Evidence (Plain English summary). National Institute for Health and Care Research. 26 September 2022. doi:10.3310/nihrevidence_53632. S2CID   252562000. Archived from the original on 28 September 2022. Retrieved 28 September 2022.
  162. Bruce J, Mazuquin B, Mistry P, Rees S, Canaway A, Hossain A, et al. (February 2022). "Exercise to prevent shoulder problems after breast cancer surgery: the PROSPER RCT". Health Technology Assessment. 26 (15): 1–124. doi: 10.3310/JKNZ2003 . PMID   35220995. S2CID   247157545.
  163. 1 2 3 Tannock IF, Ahles TA, Ganz PA, van Dam FS (1 June 2004). "Cognitive Impairment Associated With Chemotherapy for Cancer: Report of a Workshop". Journal of Clinical Oncology. 22 (11): 2233–2239. doi:10.1200/JCO.2004.08.094. ISSN   0732-183X.
  164. 1 2 3 4 Yang Y, Hendrix CC (2018). "Cancer-Related Cognitive Impairment in Breast Cancer Patients: Influences of Psychological Variables". Asia-Pacific Journal of Oncology Nursing. 5 (3): 296–306. doi: 10.4103/apjon.apjon_16_18 .
  165. 1 2 3 Matsuda T, Takayama T, Tashiro M, Nakamura Y, Ohashi Y, Shimozuma K (2005). "Mild cognitive impairment after adjuvant chemotherapy in breast cancer patients - evaluation of appropriate research design and methodology to measure symptoms". Breast Cancer. 12 (4): 279–287. doi:10.2325/jbcs.12.279. ISSN   1340-6868.
  166. 1 2 3 Hermelink K (1 May 2015). "Chemotherapy and Cognitive Function in Breast Cancer Patients: The So-Called Chemo Brain". JNCI Monographs. 2015 (51): 67–69. doi:10.1093/jncimonographs/lgv009. ISSN   1052-6773.
  167. Lindner OC, Phillips B, McCabe MG, Mayes A, Wearden A, Varese F, et al. (2014). "A meta-analysis of cognitive impairment following adult cancer chemotherapy". Neuropsychology. 28 (5): 726–740. doi:10.1037/neu0000064. ISSN   1931-1559. PMC   4143183 . PMID   24635712.
  168. Hutchinson AD, Hosking JR, Kichenadasse G, Mattiske JK, Wilson C (2012). "Objective and subjective cognitive impairment following chemotherapy for cancer: A systematic review". Cancer Treatment Reviews. 38 (7): 926–934. doi:10.1016/j.ctrv.2012.05.002. PMID   22658913.
  169. Silverman DH, Dy CJ, Castellon SA, Lai J, Pio BS, Abraham L, et al. (2007). "Altered frontocortical, cerebellar, and basal ganglia activity in adjuvant-treated breast cancer survivors 5–10 years after chemotherapy". Breast Cancer Research and Treatment. 103 (3): 303–311. doi:10.1007/s10549-006-9380-z. ISSN   0167-6806. PMID   17009108.
  170. Nelson CJ, Nandy N, Roth AJ (2007). "Chemotherapy and cognitive deficits: Mechanisms, findings, and potential interventions". Palliative and Supportive Care. 5 (3): 273–280. doi:10.1017/S1478951507000442. ISSN   1478-9515. PMID   17969831.
  171. Pendergrass JC, Targum SD, Harrison JE (2018). "Cognitive Impairment Associated with Cancer". Innovations in Clinical Neuroscience. 15 (1–2): 36–44. ISSN   2158-8333. PMC   5819720 . PMID   29497579.
  172. Jassim GA, Doherty S, Whitford DL, Khashan AS (January 2023). "Psychological interventions for women with non-metastatic breast cancer". The Cochrane Database of Systematic Reviews. 2023 (1): CD008729. doi:10.1002/14651858.CD008729.pub3. PMC   9832339 . PMID   36628983.
  173. 1 2 Lange M, Joly F, Vardy J, Ahles T, Dubois M, Tron L, et al. (2019). "Cancer-related cognitive impairment: an update on state of the art, detection, and management strategies in cancer survivors". Annals of Oncology. 30 (12): 1925–1940. doi:10.1093/annonc/mdz410. PMC   8109411 . PMID   31617564.
  174. 1 2 Janelsins MC, Kesler SR, Ahles TA, Morrow GR (2014). "Prevalence, mechanisms, and management of cancer-related cognitive impairment". International Review of Psychiatry. 26 (1): 102–113. doi:10.3109/09540261.2013.864260. ISSN   0954-0261. PMC   4084673 . PMID   24716504.
  175. Lahart IM, Metsios GS, Nevill AM, Carmichael AR (January 2018). "Physical activity for women with breast cancer after adjuvant therapy". The Cochrane Database of Systematic Reviews. 1 (1): CD011292. doi:10.1002/14651858.cd011292.pub2. PMC   6491330 . PMID   29376559.
  176. Biegler KA, Alejandro Chaoul M, Cohen L (2009). "Cancer, cognitive impairment, and meditation". Acta Oncologica. 48 (1): 18–26. doi:10.1080/02841860802415535. ISSN   0284-186X.
  177. Galimzhanov A, Istanbuly S, Tun HN, Ozbay B, Alasnag M, Ky B, et al. (July 2023). "Cardiovascular outcomes in breast cancer survivors: a systematic review and meta-analysis". European Journal of Preventive Cardiology. 30 (18): 2018–2031. doi: 10.1093/eurjpc/zwad243 . PMID   37499186.
  178. Hayes & Lippman 2022, Table 79-2.
  179. "Surgery Choices for Women with Early Stage Breast Cancer" (PDF). National Cancer Institute and the National Research Center for Women & Families. August 2004. Archived from the original (PDF) on 13 August 2013.
  180. Peppercorn J (2009). "Breast Cancer in Women Under 40". Oncology. 23 (6): 465–74. PMID   19544685. Archived from the original on 16 June 2009.
  181. "WHO Disease and injury country estimates". World Health Organization. 2009. Archived from the original on 11 November 2009. Retrieved 11 November 2009.
  182. 1 2 3 4 "Breast cancer". World Health Organization. 12 March 2024. Retrieved 29 March 2024.
  183. 1 2 3 Harbeck et al. 2019, Demographics, incidence, and mortality.
  184. Hayes & Lippman 2022, Clinical, Hormonal, and Other Nongenetic Risk Factors.
  185. Reeder JG, Vogel VG (2008). "Breast Cancer Prevention". Advances in Breast Cancer Management, Second Edition. Cancer Treatment and Research. Vol. 141. pp. 149–64. doi:10.1007/978-0-387-73161-2_10. ISBN   978-0-387-73160-5. PMID   18274088.
  186. Breast Cancer: Breast Cancer in Young Women Archived 10 September 2009 at the Wayback Machine WebMD. Retrieved 9 September 2009
  187. 1 2 3 4 5 6 7 8 9 10 Olson JS (2002). Bathsheba's breast: women, cancer & history. The Johns Hopkins University Press. ISBN   978-0-8018-6936-5.
  188. 1 2 "Oldest evidence of breast cancer found in Egyptian skeleton". Reuters. 24 March 2015. Archived from the original on 27 March 2015. Retrieved 25 March 2015.
  189. "The History of Cancer". American Cancer Society. 25 March 2002. Archived from the original on 9 October 2006. Retrieved 9 October 2006.
  190. Yalom M (1997). A history of the breast. New York: Alfred A. Knopf. p.  234. ISBN   978-0-679-43459-7.
  191. Faguet G (2015). "Chapter 2: An Historical Overview: From Prehistory to WWII. From Medieval Europe to World War II". The Conquest of Cancer: A Distant Goal. Springer. p. 24. ISBN   978-94-017-9165-6.
  192. Kaartinen M (2013). "Chapter 2: "But Sad Resources": Treating Cancer in the Eighteenth Century". Breast cancer in the eighteenth century. London: Pickering & Chatto. p. 53. ISBN   978-1-84893-364-4.
  193. 1 2 3 Winchester DJ, Winchester DP, Hudis CA, Norton L (2006). Breast Cancer. PMPH-USA. ISBN   978-1-55009-272-1.
  194. 1 2 3 de Moulin D (2013). A short history of breast cancer. Springer Science & Business Media. ISBN   978-94-017-0601-8.
  195. Boddice RG (2014). Pain and Emotion in Modern History. Springer. p. 24. ISBN   978-1-137-37243-7.
  196. Macintyre IM (June 2011). "Scientific surgeon of the Enlightenment or 'plagiarist in everything': a reappraisal of Benjamin Bell (1749–1806)". The Journal of the Royal College of Physicians of Edinburgh. 41 (2): 174–81. doi: 10.4997/JRCPE.2011.211 . PMID   21677925. Open Access logo PLoS transparent.svg
  197. Aronowitz RA (2007). Unnatural history: breast cancer and American society. Cambridge, UK: Cambridge University Press. pp.  22–24. ISBN   978-0-521-82249-7.
  198. Scientific American, "The Treatment of Cancer by Pressure". Munn & Company. 10 August 1878. p. 86.
  199. Morabia A (2004). A History of Epidemiologic Methods and Concepts. Boston: Birkhauser. pp. 301–302. ISBN   978-3-7643-6818-0. Archived from the original on 14 January 2023. Retrieved 31 December 2007.
  200. 1 2 Knopf-Newman MJ (2004). Beyond Slash, Burn, and Poison: Transforming Breast Cancer Stories Into Action. Rutgers University Press. ISBN   978-0-8135-3471-8.
  201. Lacroix M (2011). A Concise History of Breast Cancer. USA: Nova Science Publishers. pp. 59–68. ISBN   978-1-61122-305-7.
  202. 1 2 3 4 5 6 7 8 9 Sulik GA (2010). Pink Ribbon Blues: How Breast Cancer Culture Undermines Women's Health . USA: Oxford University Press. ISBN   978-0-19-974045-1. OCLC   535493589.
  203. Riter B. "History of Breast Cancer Advocacy". Cancer Resource Center of the Finger Lakes. Archived from the original on 23 June 2013. Retrieved 29 June 2013.
  204. 1 2 Klawiter M (2008). The Biopolitics of Breast Cancer: Changing Cultures of Disease and Activism. University of Minnesota Press. ISBN   978-0-8166-5107-8.
  205. Landeman A (11 June 2008). "Pinkwashing: Can Shopping Cure Breast Cancer?". Center for Media and Democracy. Archived from the original on 5 June 2011.
  206. Mulholland A (9 October 2010). "Breast cancer month overshadowed by 'pinkwashing'". . Archived from the original on 12 October 2010.
  207. King S (2006). Pink ribbons, inc.: breast cancer and the politics of philanthropy. Minneapolis: University of Minnesota Press. ISBN   0-8166-4898-0.
  208. Ehrenreich B (November 2001). "Welcome to Cancerland". Harper's Magazine. Archived from the original on 20 November 2010.
  209. 1 2 Aschwanden C (17 August 2009). "The Trouble with Mammograms". Los Angeles Times . Archived from the original on 4 December 2010.
  210. Olopade OI, Falkson CI (2010). Breast Cancer in Women of African Descent. Springer Science & Business Media. p. 5. ISBN   978-1-4020-3664-4.
  211. 1 2 3 4 Yedjou CG, Sims JN, Miele L, Noubissi F, Lowe L, Fonseca DD, et al. (3 January 2020). "Health and Racial Disparity in Breast Cancer". Breast Cancer Metastasis and Drug Resistance. Advances in Experimental Medicine and Biology. Vol. 1152. pp. 31–49. doi:10.1007/978-3-030-20301-6_3. ISBN   978-3-030-20300-9. PMC   6941147 . PMID   31456178.
  212. Baird J, Yogeswaran G, Oni G, Wilson EE (January 2021). "What can be done to encourage women from Black, Asian and minority ethnic backgrounds to attend breast screening? A qualitative synthesis of barriers and facilitators". Public Health. 190: 152–159. doi:10.1016/j.puhe.2020.10.013. PMID   33419526. S2CID   231300410. Archived from the original on 18 April 2023. Retrieved 23 February 2023.
  213. 1 2 "Reproductive History and Cancer Risk". National Cancer Institute. 30 November 2016. Archived from the original on 4 August 2019. Retrieved 22 August 2019.
  214. Azim HA, Santoro L, Russell-Edu W, Pentheroudakis G, Pavlidis N, Peccatori FA (November 2012). "Prognosis of pregnancy-associated breast cancer: a meta-analysis of 30 studies". Cancer Treatment Reviews. 38 (7): 834–42. doi:10.1016/j.ctrv.2012.06.004. PMID   22785217.
  215. Schedin P (April 2006). "Pregnancy-associated breast cancer and metastasis". Nature Reviews. Cancer. 6 (4): 281–91. doi:10.1038/nrc1839. PMID   16557280. S2CID   9085879.
  216. 1 2 3 4 5 6 7 Yarbro CH, Wujcik D, Gobel BH, eds. (2011). Cancer nursing: principles and practice (7th ed.). Jones & Bartlett Publishers. pp. 901–905. ISBN   978-1-4496-1829-2.
  217. 1 2 Gonçalves V, Sehovic I, Quinn G (2013). "Childbearing attitudes and decisions of young breast cancer survivors: a systematic review". Human Reproduction Update. 20 (2): 279–92. doi:10.1093/humupd/dmt039.